US20190022013A1 - Soft-chew tablet pharmaceutical formulations - Google Patents

Soft-chew tablet pharmaceutical formulations Download PDF

Info

Publication number
US20190022013A1
US20190022013A1 US16/140,477 US201816140477A US2019022013A1 US 20190022013 A1 US20190022013 A1 US 20190022013A1 US 201816140477 A US201816140477 A US 201816140477A US 2019022013 A1 US2019022013 A1 US 2019022013A1
Authority
US
United States
Prior art keywords
tablet
ingredient
percent
agents
soft
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/140,477
Inventor
Manesh A. DIXIT
Vaibhav L. PAWAR
Rushi R. PATEL
Mineshkumar D. PATEL
Amol SOMWANSHI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Uspharma Ltd
Original Assignee
First Time Us Generics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/067443 external-priority patent/WO2017106812A1/en
Application filed by First Time Us Generics LLC filed Critical First Time Us Generics LLC
Priority to US16/140,477 priority Critical patent/US20190022013A1/en
Assigned to FIRST TIME US GENERICS LLC reassignment FIRST TIME US GENERICS LLC NUNC PRO TUNC ASSIGNMENT (SEE DOCUMENT FOR DETAILS). Assignors: PATEL, Mineshkumar, DIXIT, MANESH A, PATEL, Rushi, PAWAR, VAIBHAV, SOMWANSHI, Amol
Publication of US20190022013A1 publication Critical patent/US20190022013A1/en
Priority to US16/894,514 priority patent/US11633361B2/en
Priority to US17/893,265 priority patent/US20220409547A1/en
Assigned to USpharma Ltd. reassignment USpharma Ltd. NUNC PRO TUNC ASSIGNMENT (SEE DOCUMENT FOR DETAILS). Assignors: FIRST TIME US GENERICS LLC
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Definitions

  • the present invention relates to products and processes for the manufacture of soft-chewable tablet pharmaceutical or nutritional dosage forms, for the oral administration of active pharmaceutical ingredients or nutritional agents.
  • Chewable pharmaceutical dosage units such as chewable tablets and soft-chewable tablets, are known and have been commercialized for use with pediatric, geriatric, and involuntary patient populations. Such dosage forms have also been used for subjects that, by instinct, will not accept the medication meant to be swallowed (e.g., animals). Chewable tablets are also useful with competent patients as an alternative to tablets or capsules that must be swallowed whole. The formulation of a drug into a chewable dosage form can increase patient acceptance of a medication in patients that resist or are unable to swallow conventional tablets or capsules.
  • Conventional dosage forms such as chewable compressed tablets, using conventional ingredients, can make the tablet gritty or otherwise unappealing to many patients.
  • tablets compressed on a compression machine are formulated and processed so the tablets have hardness of more than ten kiloponds (10 kp). Tablets having lower hardness levels are discouraged in the prior art to keep the tablet friability acceptable.
  • a process for manufacturing soft-chewable dosage form for drug delivery is described in U.S. Pat. No. 6,387,381. It discloses a soft-chewable medication vehicle for drug delivery of an active ingredient to animal or human subjects, not containing ingredients of animal origin, without use of heat and without addition of water.
  • the formed mixture was formed into individual chunks using a Formax F6TM molding machine with dies for production of chunk-like shapes, and packaged for storage.
  • Machines for the production of molded food patties have been described to be useful for the manufacturing of soft-chews for administration to non-human animals.
  • Such machines are molding machines that have been originally developed for use in producing molded food products, for example the Formax F6TM molding machine made by the Formax Corporation.
  • extruders, forming machines and rotary molding machines exhibit problems associated with the weight and physical forms of a final dosage form.
  • the use of such technologies may require conditioning of the final dosage form (e.g. drying or curing final formed structure) for consolidation of shape and structure of formed dosage form.
  • the use of such technologies, equipment and processes is complex, cumbersome, and not traditionally employed by typical pharmaceutical manufacturing facilities producing solid oral dosage forms.
  • the present invention overcomes the disadvantages and shortcomings of known chewable dosage forms by providing a simplified manufacturing process for soft-chewable dosage unit formulation comprising a highly palatable composition to patients, which is formed by conventional compression techniques using conventional pharmaceutical equipment, such as a rotary tablet press.
  • the compressed soft-chew dosage forms of the current invention have hardness of less than 2 kp, or may have hardness of less than 1 kp, or may have no measurable hardness when tested with a conventional tablet hardness tester. Despite the low hardness, such compressed soft tablets have friability of less than 1.0%, or less than 0.5%, or less than 0.1% for 100 rotations (according to United States Pharmacopeia (USP) test ⁇ 1216>); 200 rotations or 300 rotations.
  • USP United States Pharmacopeia
  • Dosage forms of the present invention include palatable, soft-chewable pharmaceutical compositions for oral administration to an involuntary subject population (e.g., very young children, senile patients, animals, etc.) that includes a therapeutically effective amount of a pharmaceutically active ingredient susceptible to abuse, in an immediate or controlled release form, and a palatability improving agent in an amount sufficient make the pharmaceutical composition palatable to the subject population.
  • an involuntary subject population is defined as patients who cannot be conventionally instructed to chew and/or swallow conventional hard chew tablets or capsules.
  • a chewable dosage unit form is an important factor in the acceptance of oral dosage forms by patients in need of medication.
  • Soft-chewable tablet dosage units having a soft texture, pleasant mouthfeel, and palatable taste with adequate flavoring agents, provide a solution to such problems.
  • these features can address the problem of the disagreeable taste of many active pharmaceutical ingredients.
  • Appropriate chewable dosage form can also address texture problems caused by dry dusty, granular, and pulverant properties of many pharmaceutical ingredients.
  • the soft-chewable formulations are prepared according to methods conventional in the art, such as wet or dry granulation processes.
  • a soft-chewable pharmaceutical dosage unit is a solid pharmaceutical dosage unit at room temperature that has low hardness and higher moisture content than a conventional tablet or hard chewable tablet. Such a dosage unit exhibits a plastic rheological behavior and can be formed by many manufacturing processes described in prior art into many different shapes. A soft-chewable pharmaceutical dosage unit after forming should be dimensionally stable. The ingredients of such a soft-chewable pharmaceutical dosage unit may be of pharmaceutical grade.
  • a semi plastic oral dosage form unit has a soft texture and hardness such that the unit is intended to be chewed and swallowed.
  • the texture of the unit is such that it does not appreciably dissolve in the mouth.
  • FIG. 1 is a plot of the texture characterization and comparison to marketed soft-chewable tablet for data in Example 1, showing load peaks applied at 2, 9, and 10 seconds;
  • FIG. 2 is a plot of the texture characterization and comparison to marketed soft-chewable tablet for data in Example 4, showing load peaks applied at 2, and 15 seconds;
  • FIG. 3 is a plot of the dissolution vs. time in 0.1 N HCl, USP II apparatus, 900 ml, 100 rpm for data in Tables 7 and 8;
  • FIG. 4 is a plot of the percent drug release vs. time in acetate buffer, USP II, 900 ml, 100 rpm for data in Tables 9 and 10;
  • FIG. 5 is a plot of the percent drug release vs. time in phosphate buffer, pH 7.5, USP II apparatus, 900 ml, 100 rpm for data in Tables 11 and 12;
  • FIG. 6 is a plot of the comparative dissolution of data in Tables 14 and 15, glycine buffer pH 3.0, USP II apparatus, 900 ml, 75 rpm;
  • FIG. 7 is a plot of the percent drug release v/s time in citrate buffer pH 4.0, USP II apparatus, 900 ml, 100 rpm for data in Table 16.
  • tablets of the present invention will have a uniform composition.
  • dosage forms are formed by making a soft chew mass.
  • the soft chew mass includes various excipients including lipid and dry ingredients, granulation ingredients (granulation aid ingredients and intra-granulation ingredients), extra-granulation ingredients, and active ingredients.
  • granulation ingredients granulation aid ingredients and intra-granulation ingredients
  • extra-granulation ingredients extra-granulation ingredients
  • active ingredients active ingredients.
  • granules of the soft chew mass are formed, passed through appropriate screens for sizing, and then compressed using a rotary tablet press.
  • the solid, soft chewable or semi-plastic oral dosage forms of the present invention have a soft texture, low hardness, and may be chewed and swallowed.
  • the texture of the unit is such that it does not appreciably dissolve in the mouth.
  • Dosage forms of the present invention may be designed to be chewed and swallowed by a human or an animal.
  • a tablet press is a mechanical device that compresses powder into tablets of uniform size and weight.
  • a press can be used to manufacture tablets/pellets of a wide variety of materials, including pharmaceuticals, cleaning products, and cosmetics.
  • the rotary-type is generally more widely used, because it facilitates high production performance with narrow weight variation along with ease of use.
  • fluid refers a material that is flowable or malleable.
  • a fluid material may be a viscous liquid, with a viscosity comparable, for example, to water, vegetable oil, honey, or peanut butter.
  • One aspect of the present invention relates to a solid, soft chewable or semi-plastic oral dosage form system including at least one active ingredient.
  • the solid, soft chewable or semi-plastic oral dosage forms of the present invention are obtained by compression on a rotary tablet press.
  • the solid, soft chewable or semi-plastic oral dosage forms of the present invention exhibit a hardness of less than two kiloponds (2 kp) when measured on tablet hardness tester. More preferably, the solid, soft chewable or semi-plastic oral dosage forms of the present invention exhibit a hardness of less than one kilopond (1 kp) when measured on tablet hardness tester.
  • the solid, soft chewable or semi-plastic oral dosage forms of the present invention exhibit no hardness when measured on tablet hardness tester.
  • the solid, soft chewable or semi-plastic oral dosage forms of the present invention have a friability of less than about 1% at 100 rotations.
  • a soft-chew mass is formed by blending appropriate active ingredients and excipients.
  • the soft-chew mass is compressed in tablet press to provide tablets with minimal hardness.
  • the tablets of the present invention have a hardness less than or equal to about two kiloponds (2 kp). More preferably, the tablets of the present invention have a hardness of less than or equal to about one kilopond (1 kp). Even more preferably, the tablets of the present invention have no measurable hardness in a tablet hardness testing apparatus.
  • a process for the manufacture of a compressed soft-chew tablet unit dosage form for the oral administration of an active ingredient, in which a soft-chew tablet or semi-plastic tablet is formed by compressing a soft-chew mass on a compression press, and wherein the soft-chew tablets have a hardness of less than about two kiloponds (2 kp) and a friability of less than about one percent (1%) at three-hundred (300) rotations.
  • a process for the manufacture of a compressed soft-chew tablet unit dosage form for the oral administration of an active ingredient, in which a soft-chew mass mixture is provided including an active ingredient, wherein the soft-chew mass is a granulate (granules) formed with a granulation and sifting step, and wherein the soft-chew mass granulate is pressed into tablets using a tablet press, and wherein the soft-chew tablets have a hardness of less than about two kiloponds (2 kp) and a friability of less than about one percent (1%) at three-hundred (300) rotations.
  • an edible compressed soft-chew tablet or semi plastic oral unit dosage form is manufactured by a process of: (a) mixing at least one active ingredient with at least one dry or liquid component to form a liquid premix; (b) blending dry ingredients having at least one of each of a bulking agent, a lipid, a flavoring agent, a disintegrating agent, a binding agent, a surfactant, a preservative, a lubricating agent, and an anti-sticking to form a uniform dry ingredient mixture; (c) blending the premix and the uniform dry ingredient mixture to form a granulated compacted soft-chew mass; (d) sifting the granulated compacted soft-chew mass through at least one sifting screen to form uniform granules of the soft-chew mass; and (e) adding a lubricant or anti sticking agent to the uniform granules of the soft-chew mass and compressing the resulting mixture in a tablet press to from soft
  • a first mixture is a fluid premix containing the active ingredient
  • a second mixture is a blend of dry ingredients.
  • the fluid premix and dry ingredient blend may be blended together to form a soft-chew mass.
  • active ingredient or “active agent” refers to an active pharmaceutical ingredient or nutritional agent.
  • An active pharmaceutical ingredient is a substance used in a pharmaceutical dosage form, intended to furnish pharmacological activity or to otherwise have direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to have direct effect in restoring, correcting or modifying physiological functions in a patient population (humans or animals).
  • a nutritional agent may include vitamins, minerals, glycosaminoglycan or its active members, amino acids or combination thereof that are useful in human or animal nutrition.
  • An active pharmaceutical ingredient may include any approved or experimental drug.
  • approved it is meant that the drug is approved for human or veterinary use by a regulatory agency in any country that makes such drug approvals.
  • the pharmaceutically active ingredient may be selected from an anesthetic agent, anthelmintic agent, analgesic agent, steroid, corticosteroid agent, non-steroidal anti-inflammatory drug (NSAID) agent, antiemetic agent, anti-thyroidal agent, parasiticidal agent, appetite stimulant, antihistamine agent, antifungal agent, antiprotozoal agent, or anti-depressant.
  • NSAID non-steroidal anti-inflammatory drug
  • the active ingredient may be in granular form and coated, or further coated, with a suitable coating.
  • the coating could be a coating polymer that coats and protects the active ingredient, or masks an offensive taste and/or offensive odor.
  • the coating could be a functional coating (e.g., an extended-release coating, delayed-release coating, controlled-release coating, barrier coating, or a combination thereof).
  • the active ingredient may be dissolved, emulsified, or suspended in a non-aqueous solvent before addition.
  • the nutritional or pharmaceutically active ingredient may be soluble, partially soluble, or insoluble in water.
  • the active ingredient is added to the composition by dry blending.
  • the active ingredient may be conjugated with other ingredients, such as cyclodextrins, surfactants, solubility or bioavailability enhancers, etc., to inhibit interactions with other excipients or with the environment, or to promote the chemical stability, improve solubility, enhance bioavailability, or improve the palatability of the nutritional ingredient or pharmaceutically active agent.
  • the pharmaceutically active ingredient may be incorporated into a novel drug delivery system, such as microspheres, microcapsules, liposomes, niosomes, nanoparticles, microemulsions, or nanoemulsions to protect the drug or permit organ targeting.
  • the rate of release of the active ingredient may be modulated or controlled by, for example, the use of controlled or sustained release agents (e.g., polymers) or by using excipients (e.g., disintegrants) that promote in rapid release, as appropriate.
  • controlled or sustained release agents e.g., polymers
  • excipients e.g., disintegrants
  • a single excipient has more than one function in the formulation of the present invention.
  • propylene glycol and glycerol may be present and have a simultaneous role as a plasticizer, humectants, antimicrobial agents, or any combination of any two or more thereof, in this formulation.
  • Lipids may have a role as a lubricant, plasticizer, binders, or any combination of any two or more thereof. Any suitable excipient may be used.
  • Lipids may include, but are not limited to, mineral oils, liquid vegetable oils, or solid hydrogenated vegetable oils. Vegetable oils may include, but are not limited to, soybean oil, olive oil, flaxseed oil, canola oil, or corn oil.
  • the active ingredient may be mixed with a lipid (e.g., vegetable oil) to form a premix.
  • a lipid e.g., vegetable oil
  • the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes a texturing agent, selected from the group comprising of modified corn starches, polyols, poly(ethylene) oxide, microcrystalline cellulose co-processed with guar gum and the like.
  • a polyol may include propylene glycol, glycerin, polyethylene glycol and mixtures thereof.
  • the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes one or more fillers.
  • a filler may be used to increase the total mass of the chewable formulation to a manageable size or to enhance the flow properties of final powder or granules to be compressed in a rotary tablet press.
  • the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes a binding agent.
  • the binding agent may be polyethylene glycol.
  • the polyethylene glycol may be admixed to dry ingredients for mixing.
  • the polyethylene glycol may be melted and added to at least one other dry ingredient and mixed to form the uniform dry ingredient mixture.
  • the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes microcrystalline cellulose as a bulking agent.
  • the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes lipid and microcrystalline cellulose in a ratio of about 2:1 to about 1:2.5, w/w, and wherein the tablet is manufactured by compression on a tablet press.
  • one or more diluents may be used in combination with silicified microcrystalline cellulose.
  • diluents include starches and their derivatives (e.g., hydrogenated starch hydrosylate), celluloses and their derivatives (e.g., cellulose acetate), protein matrices (soy protein, dextrates, wheat gluten, whey, corn cob, corn gluten), carbohydrates (e.g., maltodextrin, polydextrose), sugars and sugar alcohols (glucose, lactose, fructose, maltose, dextrose, sucrose, maltitol, xylitol, isomalt, mannitol), silicates, calcium phosphates, calcium sulfate, dextrates, kaolin, magnesium carbonate, polymethacrylates, talc, salts (e.g., sodium chloride) or any combination of any two or more thereof.
  • starches and their derivatives e.g
  • the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes a starch, or a modified starch, or a mixture of starch and a modified starch.
  • diluents may also serve a role in fat or oil absorption, disintegration, and binding, providing nutrition, lubrication or any combination of any two or more thereof.
  • the diluents may also be used for taste masking or modifying texture, for example microcrystalline cellulose co-processed with guar gum and/or modified corn starches.
  • the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes one or more binders. Binders improve the binding properties of the compacted mass, to assist the formation of compact dosage units. Any suitable binder known in the art may be used.
  • gums e.g., xanthan gum and guar gum
  • alginates e.g., methylcellulose and microcrystalline cellulose
  • lipids e.g., fats and oils
  • starches and their derivatives e.g., dextrins, povidones, silicates, polymethacrylates, polyethylene oxides, waxes, chitosan, polycarbophil,
  • the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes one or more palatability enhancers.
  • Palatability enhancers improve the taste of material that is chewed.
  • palatability enhancers may improve the palatability of soft-chewable formulations comprising bitter, acrid, obnoxious, unpleasant, or otherwise unpalatable nutritional or pharmaceutically active agents.
  • the palatability enhancer is a taste masking agent, a flavoring agent, an aroma modifier, or a taste modifier, or any combination of any two or more thereof.
  • Flavoring agents may be used to improve the palatability of the chewable tablets. Any type of flavoring agent can be used provided it improves the palatability of the product, typically by improving either its taste and/or smell. The use of a flavoring agent may also assist with dose compliance. Flavors can be natural (derived from animal or plant sources), semisynthetic, or artificial. In one embodiment, the flavoring agent is an artificial flavoring agent, semi-synthetic flavoring agent, a natural flavoring agent, or nature identical flavoring agent.
  • the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes liquid components that are absorbed on the surface of a lipid absorbing pharmaceutical ingredient selected from one or more of microcrystalline cellulose, silicified microcrystalline cellulose, and a combination of microcrystalline cellulose and guar gum.
  • the liquid components absorbed on the surface of the lipid absorbing pharmaceutical ingredient may be mixed with the dry ingredient mixture and then sifted again through at least one sifting screen to form further granules of the soft-chew composition mixture.
  • a nutritional agent or a pharmaceutically active ingredient is admixed with the liquid components prior to mixing with the lipid absorbing pharmaceutical ingredient.
  • plasticizers may be used to the formulation to improve plasticity and malleability of dosage units of the present invention.
  • a plasticizer may be selected from alcohols, glycols (such as propylene glycol), lanolin, wool fat, liquid paraffin, mineral oil, petrolatum, benzyl phenylformate, chlorobutanol, diethyl phthalate, glycerol, polyethylene glycol, propylene glycol, sorbitol, triacetin, benzyl phenyl formate, dibutyl sebacate, tributyl citrate, triethyl citrate, or any combination of any two or more thereof.
  • Other plasticizers known in the art may also be used.
  • the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes a non-active ingredient including of one or more of a starch, a polysaccharide, a humectant, a polyol, water-soluble poly(ethylene oxide) resin.
  • the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes a humectant.
  • a humectant is used to retain moisture in the dosage unit.
  • a humectant of value in this invention may be selected from sodium and potassium chloride, benzalkonium chloride, aluminum silicate, sodium propionates, sodium and potassium phosphates, sugars, sulfites, hydrogenated starch hydrosylate, etc.
  • Liquid humectants include, but are not limited to, glycols, polyols, sugar alcohols, vegetable oils and mineral oil, hydrogenated vegetable oils, hydrocarbons, triacetin, liquid paraffin, or any combination of any two or more thereof. Other humectants known in the art may also be used.
  • the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes an antioxidant.
  • An antioxidant inhibits oxidation and may be of benefit as a preservative, or to maintain the chemical stability of an active or inactive ingredient.
  • An antioxidant may be selected from propyl gallate, ascorbic acid and its derivatives, sodium formaldehyde sulfoxylate, malic acid, fumaric acid, editic acid, thiols, polyphenols, sodium EDT A, sodium ascorbate, sodium metabisulfite, butylated hydroxytoluene, butylated hydroxyanisole, butylated hydroxyanisole and butylated hydroxytoluene co-processed with zea mays oil or natural substances such as flavanoids, tocopherols, carotenes, cysteine, or any combination of any two or more thereof.
  • antioxidants known in the art may also be used.
  • the antioxidants are generally added to the formulation in amounts of from about one one-hundredth percent (0.01%) to about two percent (2.0%), based upon total weight of the formulation, with about one one-hundredth percent (0.01%) to about one percent (1.0%) being especially preferred.
  • the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes a preservative selected from the group including parabens (methylparaben and/or propylparaben), benzalkonium chloride, benzethonium chloride, benzoic acid, citric acid, fumaric acid, benzyl alcohol, bronopol, butylparaben, cetrimide, chlorhexidine, chlorobutanol, chlorocresol, cresol, ethylparaben, imidurea, methylparaben, phenol, phenoxyethanol, phenylethyl alcohol, potassium sorbate, sodium benzoate, sodium propionate, sorbic acid, thimerosal, and quaternary ammonium compounds.
  • a preservative selected from the group including parabens (methylparaben and/or propylparaben), benzalkonium chloride, benzethonium chloride, benzoic acid, citric acid, fuma
  • the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes a nonaqueous solvent, for example glycerin or sorbitol.
  • a non-aqueous solvent may disperse, solubilize or enhance solubilization of the nutritional or pharmaceutically active agent.
  • the non-aqueous solvent may also enhance the binding of the formulation and the consistency and texture of the soft-chewable dosage form.
  • the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes a disintegrating agent.
  • a disintegrating agent may be used to enable the inventive chewable tablets to break down on contact with water, saliva, or gastric fluid in the stomach to quickly release the active ingredient.
  • a disintegrating agent may be selected from povidones, croscarmellose sodium, sodium starch glycollate, celluloses and their derivatives, starches and their derivatives, gelatin, silicon dioxide, or any combination of any two or more thereof. Other disintegrating agents known in the art may also be used. Disintegration may be tested and measured using United States Pharmacopeia (USP) Disintegration Test ⁇ 701> for uncoated tablets, using water as medium.
  • USP United States Pharmacopeia
  • a granulated compacted soft-chew mass is formed, and the mass is dried by equipment using direct or indirect conduction heat applied to a static solid bed, a moving solid bed, or a fluidized solid bed.
  • the granulated mass may be dried at room temperature, for example about twenty-five degrees Celsius (25° C.) plus-or-minus ten degrees Celsius (10° C.).
  • the granulated mass may be dried at a controlled temperature of about fifty degrees Celsius (50° C.) or less.
  • the process of this invention may include sifting, or milling, of dry components or a granulated mass, or a mixture of both through sifting screens with mesh sizes commonly known in the art.
  • Mesh sizes for sifting screens may include Mesh #4 or 5 or 6 or 7 or 8 or 10 or 12 or 14 or 16 or 18 or 20 or 25 or 30 or 35 or 40 or 45 or 50 or 60 or other mesh sizes commonly known in the art.
  • Components may be sifted through at two or more screens with different mesh sizes one after other in gradual or random order of mesh sizes.
  • the dry ingredient mixture or the granulated compacted soft-chew mass is sifted through sifting equipment using impaction, attrition, compression or cutting.
  • the dry ingredient mixture or the granulated compacted soft-chew mass is uniformly mixed using equipment using diffusion mixing, convection mixing or pneumatic mixing.
  • the process of this invention may employ pre-compression force applied to the granulated compacted soft-chew mass before application of main compression force for compression of soft-chews.
  • the granulated compacted soft-chew mass is fed into a compression die by gravity feed, power assisted feed, by centrifugal force, or by compression coating.
  • the soft-chew tablets of this invention may incorporate an abuse-deterrent technology, which can include one or more of high-melting-point excipients that resist heating and injecting; taste modifiers that resist covert administration, snorting (ingestion of a powdered material through the nose) and dose dumping (extraction of active pharmaceutical ingredients (API) from tablets); water insoluble excipients that resist extraction and drink adulteration; waxy excipients that resist snorting; viscosity modifiers that resist dissolution, injection and dose dumping; low-density excipients that resist drink adulteration; and dyes, that resist adulteration.
  • an abuse-deterrent technology can include one or more of high-melting-point excipients that resist heating and injecting; taste modifiers that resist covert administration, snorting (ingestion of a powdered material through the nose) and dose dumping (extraction of active pharmaceutical ingredients (API) from tablets); water insoluble excipients that resist extraction and drink adulter
  • the breaking force of tablets is commonly called hardness in the pharmaceutical literature.
  • crushing strength is also frequently used to describe the resistance of tablets to the application of a compressive load.
  • the measure of the mechanical integrity of tablets is their breaking force or hardness, which is the force required to cause them to fail (i.e., break) in a specific plane.
  • Various equipment is used for hardness measurements, for example a Monsanto Hardness Tester, Stokes Hardness tester, Pfizer Hardness Tester, Strong-Cobb Hardness Tester, or Schleuniger Hardness tester. Tablet hardness can be expressed using various units depending on the equipment used for hardness measurement. The units for tablet hardness measurement are newtons, pounds, Strong-Cobb units, and kiloponds.
  • a Schleuniger Hardness tester was used, and hardness was measured in kiloponds or newtons.
  • This apparatus has two parallel platens between which a tablet is placed. A load is applied and the value of the hardness is measured.
  • the platen faces are polished smooth and precision-ground perpendicularly to the direction of movement. Perpendicularity is preserved during platen movement, and the mechanism is free of any bending or torsion displacements as the load is applied.
  • the contact faces are larger than the area of contact with the tablet.
  • the chewable formulation of this invention includes dosage units which have hardness of less than two kilopond (2 kp), preferably less than one kilopond (1 kp), and more preferably has no measurable hardness when measured with a tablet hardness tester.
  • the chewable formulation of this invention includes dosage units with hardness less than three (3.0) Strong Cobb units, preferably less than one and one-half (1.5) Strong Cobb units, or more preferably no measurable hardness when measured with a tablet hardness tester.
  • the chewable formulation of this invention includes dosage units with hardness less than five (5.0) pound, preferably less than two and one-half (2.5) pound, or more preferably no measurable hardness when measured with a tablet hardness tester.
  • the chewable formulation of this invention includes dosage units with hardness less than twenty (20.0) newtons, preferably less than ten (10) newtons, or more preferably no measurable hardness when measured with a tablet hardness tester.
  • a friability value of about one percent (1%) or less (when measured as per USP test) is desirable for tablets in order for them to withstand the stress of handling during production, packaging, and transport.
  • the formulation comprises of dosage units with friability less than one percent (1%), preferably less than one-half percent (0.5%), or more preferably less than one-tenth percent (0.1%) for one-hundred (100) rotations (per USP), or two-hundred (200) rotations, or three-hundred (300) rotations.
  • tablet hardness is traditionally kept three kilopond (3 kp) or more. As dosage form size increases, compression force is increased to produce tablet with even higher hardness.
  • the soft-chewable tablet maintains a characteristic selected from chewiness, hardness, compression energy, adhesion, cohesiveness, springiness, and modulus, and any combination of any two or more thereof (when measured by the texture analyzer as per procedure for Example 1) sufficient to provide a chewable texture.
  • the dosage unit of this invention has a weight between about one-tenth gram (0.1 g) and about ten grams (10 g). In one embodiment, the dosage unit has a weight between about one-half gram (0.5 g) and about four grams (4.0 g). In one embodiment, the dosage unit has a weight between about one-tenth gram (0.1 g) and about three grams (3.0 g). In another embodiment, the weight of the dosage unit is between about one-tenth gram (0.1 g) and about two grams (2.0 g).
  • weight of the dosage unit can be between about one-tenth gram (0.1 g) and about one gram (1.0 g); or between about one and one-tenth gram (1.1 g) and about two grams (2.0 g); or between about two and one-tenth grams (2.1 g) and about three grams (3.0 g); or between about three and one-tenth grams (3.1 g) and about four grams (4.0 g); or between about four and one-tenth grams (4.1 g) and about five grams (5.0 g).
  • the dosage unit (e.g., soft-chew) of this invention can have an imprint on at least one surface of the dosage unit.
  • this imprint can be on the top surface of the dosage unit.
  • Such imprint can be, for example, letters, numbers, logos, or symbols, etc.
  • An imprint can also be on the bottom surface.
  • the dosage unit has a score or groove on one of the surfaces. This cross score has the effect that it facilitates the dividing of the dosage unit and allows more exact dosing of the active pharmaceutical ingredient according to the body weight, and/or age of the patient.
  • Such dosage units can have different weights, dimensions and shapes that can be adapted to the weight and need of the target patient population to allow accurate dosing.
  • Dosage forms can be to different weights, dimensions and shapes known in the art.
  • the soft-chew tablets of this invention can be round, capsule-shaped, or have a modified shape.
  • the soft-chewable tablets of this invention can be packaged as bulk primary packaging, or as singular unit primary packaging.
  • Example 1 Ingredients corresponding to Example 1 are tabulated in Table 1, with the amount of each ingredient given in respective percent by weight (% w/w).
  • Texture Analysis was performed using CT3 Texture Analyzer (Brookfield Engineering) using a TA3/100 probe and twenty-five-thousand gram (25,000 g) load cell and five gram (5 g) trigger load, over four millimeters (4 mm) using two millimeter per second (2 mm/s) test speed and using a data rate of one-hundred (100) points/second. Load peaks were applied at two (2), nine (9), and ten (10) seconds. The results are plotted in FIG. 1 .
  • Tables 2 and 3 The results of a tablet characterization study are tabulated in Tables 2 and 3.
  • tablets formed in accordance with Example 1 were compared to a marketed soft-chewable tablet.
  • the marketed soft-chewable tablet was formed using an unconventional molding method.
  • the data in Table 3 was obtained using a CT3 Texture Analyzer.
  • Example 2 Ingredients corresponding to Example 2 (a conventional hard chewable tablet) are tabulated in Table 4, with the amount of each ingredient given in respective percent by weight (% w/w).
  • Texture analysis was performed using CT3 Texture Analyzer using TA/RT/KIT probe and 25,000 g load cell and 510 g trigger load, over 4 mm using 2 mm/s test speed and using data rate of 10 points/second. Load peaks were applied at 2 and 15 seconds. The results are plotted in FIG. 2 .
  • Example 2 Example 3
  • Example 4 Weight (g) 0.500 3.0 3.0 Shape Square Square Square Color Light Brown Yellow-Brown Yellow-Brown Dimension (mm) — 18 X 18 18 X 18 Thickness (mm) 4.00-5.00 7.00-8.00 8.00-9.00 Disintegration Time (min) — 10.00-15.00 20.00-21.00 Tablet Hardness (kp) 16.00-18.00 0 0 Tablet Hardness (N) 170 — 0 Tablet Friability (% w/w) — 0 0.02 LOD at 105° C. (% w/w) 6.00-7.00 — 7.00-8.00
  • Tables 7 and 8 The data in Tables 7 and 8 is presented graphically in FIG. 3 .
  • Tables 9 and 10 The data in Tables 9 and 10 is presented graphically in FIG. 4 .
  • Example 5 The results of a comparative dissolution study (in vitro analysis—multimedia dissolution testing) involving the tablets formed according to Example 5 are tabulated in Tables 14 and 15.
  • the dissolution profile of Example 5 was compared to a reference drug.
  • a paddle apparatus (USP II Apparatus) rotating at 75 rpm was used.
  • the dissolution medium consisted of a nine-hundred milliliter (900 ml) glycine buffer solution, pH 3.0.
  • Example 16 The results of a comparative dissolution study (in vitro analysis—multimedia dissolution testing) involving the tablets formed according to Example 6 are tabulated in Table 16.
  • the dissolution profile of Example 6 was compared to a reference drug.
  • a paddle apparatus (USP II Apparatus) rotating at 100 rpm was used.
  • the dissolution medium consisted of a nine-hundred milliliter (900 ml) citrate buffer solution, pH 4.0.
  • Example 9-11 Ingredients corresponding to Examples 9-11 (carprofen soft chewable tablets) are tabulated in Table 12, with the amount of each ingredient given in respective percent by weight (w/w %).
  • the active ingredient is carprofen.
  • the active strength of carprofen is about 25 mg.
  • the active strength of carprofen is about 75 mg.
  • the active strength of carprofen is about 100 mg.
  • Example Example Example Ingredient 9 10 11 Granulation Aid Carprofen 0.83 2.5 3.33 Mineral Oil 8 8 8 Sorbitol 15.5 15.5 15.5 Polyethylene Glycol (PEG-600) 6 6 6 6 Povidone (K-30) 2.3 2.3 2.3 Brown Iron Oxide 0.01 0.01 0.01 Intra-granular Ingredients Carnauba Wax 5 4 4 Silicified Microcrystalline Cellulose 19.84 19.84 19.01 Lactose 3.92 3 3 Pregelatinized Corn Starch 2 2 2 Calcium Sulfate Dihydrate 2 2 2 Croscarmellose sodium 0.1 0.35 0.35 Beef Flavor 15 15 15 15 Extra-granular Ingredients Pregelatinized Corn Starch 5 5 5 Silicified Microcrystalline Cellulose 7.5 7.5 7.5 Beef Flavor 3 3 3 Lactose 2 2 2 Flow Aid Ingredient Sodium Stearyl Fumarate 2 2 2 Total 100 100 100 100 100 100 100
  • Example 11 Weight (mg) 3860 3000 3000 3000 Shape Trapezoidal Rounded Rounded Square Square Square Color Brown Light brown Light brown Light brown to brown to brown to brown Width ⁇ Length 16.4 ⁇ 17.1 18.0 ⁇ 18.0 18.0 ⁇ 18.0 18.0 ⁇ 18.0 Top (mm) Width ⁇ Length 17.8 ⁇ 18.6 18.0 ⁇ 18.0 18.0 ⁇ 18.0 18.0 ⁇ 18.0 Bottom (mm) Thickness (mm) 9.5 8.6 8.8 8.8 Disintegration 26 20 24 26 Time (min) Hardness (N) 0 0 0 0 Friability (%) 0 0 0 0 0 0 0
  • Example 9-11 The results of a comparative dissolution study involving the tablets formed according to Examples 9-11 are tabulated in Tables 20-22, respectively.
  • the dissolution profiles of Examples 9-11 were compared to marketed products having similar active strengths.
  • a paddle apparatus rotating at 100 rpm was used.
  • Nine-hundred milliliters (900 ml) of phosphate buffer pH 7.5 was used as the dissolution medium.
  • Example 12-14 Ingredients corresponding to Examples 12-14 (carprofen soft chewable tablets) are tabulated in Table 23, with the amount of each ingredient given in respective percent by weight (% w/w).
  • the active ingredient is carprofen.
  • the active strength of carprofen is about 25 mg.
  • the active strength of carprofen is about 75 mg.
  • the active strength of carprofen is about 100 mg.
  • the results of a texture analysis of the tablets formed according to Examples 12-14 are tabulated in Table 25.
  • the texture analysis was performed using a CT3 Texture Analyzer (Brookfield Engineering) using a TA18 Probe and twenty-five-thousand gram (25,000 g) load cell and five gram (5 g) trigger load, over four millimeters (4 mm) using two millimeter per second (2 mm/s) test speed and using a data rate of twenty (20) points/second.
  • Tables 26-28 show the results accelerated stability study of the tablets formed according to Examples 12-14, respectively.
  • the tablets were packaged in a high-density polyethylene (HDPE) container and stored at a temperature of 40° C. ⁇ 2° C. and a relative humidity (RH) of 75% ⁇ 5%.
  • HDPE high-density polyethylene
  • Example 15 Ingredients corresponding to Example 15 are tabulated in Table 29.
  • the active ingredient in the formulation of Example 15 is enrofloxacin.
  • the active strength of enrofloxcin used in the Example 15 formulation was 22.7 mg or 68 mg or 136 mg.
  • Example 15 Example 15 Parameters 22.7 mg 68 mg 136 mg Weight (mg) 500 1500 3000 Shape Rounded Rounded Rounded Square Square Square Color Light brown Light brown Light brown to brown to brown to brown Area-Top (mm) 10.5 ⁇ 10.5 15.3 ⁇ 15.3 18.0 ⁇ 18.0 Width ⁇ Length Area-Bottom (mm) 10.5 ⁇ 10.5 15.3 ⁇ 15.3 18.0 ⁇ 18.0 Width ⁇ Length Thickness (mm) 4.5 6.8 9 Disintegration 5 min 7 min 9 min Time (min) Hardness (N) 0 0 0 Friability (%) 0 0 0 0 0
  • the results of a texture analysis of the tablets formed according to Example 15 are tabulated in Table 31.
  • the texture analysis was performed using a CT3 Texture Analyzer (Brookfield Engineering) using a TA18 Probe and twenty-five-thousand gram (25,000 g) load cell and five gram (5 g) trigger load, over four millimeters (4 mm) using two millimeter per second (2 mm/s) test speed and using a data rate of twenty (20) points/second.
  • Example 15 Example 15 Parameters 22.7 mg 68.0 mg 136 mg Hardness Cycle 1 (g) 3348 1994 3142 Hardness Cycle 2 (g) 1186 232 6 Deformation at 3.97 0.96 1.27 hardness (mm) Stringiness Length 0 50.37 0 (mm) Adhesiveness (mJ) 0 ⁇ 0.1 0 Cohesiveness 0.03 0.09 0 Gumminess (g) 116 185 0 Chewiness (mJ) 1.1 122.8 0 Springiness 0.25 67.84 1
  • Example 15 The results of a comparative dissolution study involving the tablets formed according to Example 15 are tabulated in Tables 32-34.
  • the dissolution profiles of Example 15 were compared to marketed products having similar active strengths.
  • a paddle apparatus rotating at 100 rpm was used.
  • Nine-hundred milliliters (900 ml) of pH 4.0 citrate buffer was used as the dissolution medium.
  • Example 16-18 Ingredients corresponding to Examples 16-18 are tabulated in Table 35, with the amount of each ingredient given in respective percent by weight (w/w %).
  • the active ingredient is enrofloxacin.
  • the active strength of enrofloxacin is about 22.7 mg.
  • the active strength of enrofloxacin is about 68 mg.
  • the active strength of enrofloxacin is about 136 mg.
  • Example Example Example Ingredient 16 17 18 Granulation Aid Ingredients Mineral Oil 7 7 7 Glycerin 16 14 16 Polyethylene Glycol (PEG-600) 4 6 4 Povidone (K-30) 0.25 0.25 0.25 Brown Iron Oxide 0.01 0.01 0.01 Intra-granular Ingredients Enrofloxacin 4.53 4.53 4.53 Carnauba wax 4 6 4 Lactose 15.21 13.71 15.21 Silicified Microcrystalline Cellulose 8.5 8 8.5 Calcium Sulfate Dihydrate 2 2 2 Beef Flavor 15 15 15 Croscarmellose Sodium 4.5 4.5 4.5 Extra-granular Ingredients Pregelatinized Starch 3 3 3 Silicified Microcrystalline Cellulose 6.3 6.3 6.3 Beef Flavor 3 3 3 3 Croscarmellose Sodium 4.5 4.5 4.5 Flow Aid Ingredients Sodium Stearyl Fumarate 2 2 2 Sodium Lauryl Sulphate 0.2 0.2 0.2 Total 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
  • Example 16 Example 17
  • the results of a texture analysis of the tablets formed according to Examples 16-18 are tabulated in Table 37.
  • the texture analysis was performed using a CT3 Texture Analyzer (Brookfield Engineering) using a TA18 Probe and twenty-five-thousand gram (25,000 g) load cell and five gram (5 g) trigger load, over four millimeters (4 mm) using two millimeter per second (2 mm/s) test speed and using a data rate of twenty (20) points/second.
  • Tables 38-40 show the results accelerated stability study of the tablets formed according to Examples 16-18, respectively.
  • the tablets were packaged in a high-density polyethylene (HDPE) container and stored at a temperature of 40° C. ⁇ 2° C. and a relative humidity (RH) of 75% ⁇ 5%.
  • HDPE high-density polyethylene
  • Example 19 Ingredients corresponding to Examples 19-23 are tabulated in Table 41, with the amount of each ingredient given in respective percent by weight (w/w %).
  • the active ingredient is deracoxib.
  • the active strength of deracoxib is about 12 mg.
  • the active strength of deracoxib is about 25 mg.
  • the active strength of deracoxib is about 50 mg.
  • the active strength of deracoxib is about 75 mg.
  • the active strength of deracoxib is about 100 mg.
  • the results of a texture analysis of the tablets formed according to Examples 19-23 are tabulated in Table 43.
  • the texture analysis was performed using a CT3 Texture Analyzer (Brookfield Engineering) using a TA18 Probe and twenty-five-thousand gram (25,000 g) load cell and five gram (5 g) trigger load, over four millimeters (4 mm) using two millimeter per second (2 mm/s) test speed and using a data rate of twenty (20) points/second.
  • Tables 49-53 show the results accelerated stability study of the tablets formed according to Examples 19-23, respectively.
  • the tablets were packaged in a high-density polyethylene (HDPE) container and stored at a temperature of 40° C. ⁇ 2° C. and a relative humidity (RH) of 75% ⁇ 5%.
  • HDPE high-density polyethylene
  • Example 24 Ingredients corresponding to Examples 24 and 25 are tabulated in Table 54, with the amount of each ingredient given in respective percent by weight (% w/w).
  • the active ingredient is marbofloxacin.
  • the active strength of marbofloxacin is about 25 mg or about 50 mg or about 100 mg.
  • the active strength of marbofloxacin is about 200 mg.
  • the results of a texture analysis of the tablets formed according to Examples 24 and 25 are tabulated in Table 56.
  • the texture analysis was performed using a CT3 Texture Analyzer (Brookfield Engineering) using a TA18 Probe and twenty-five-thousand gram (25,000 g) load cell and five gram (5 g) trigger load, over four millimeters (4 mm) using two millimeter per second (2 mm/s) test speed and using a data rate of twenty (20) points/second.
  • Example 24 The results of a comparative dissolution study involving the tablets formed according to Example 24 are tabulated in Tables 57-59.
  • the results of a comparative dissolution study involving the tablets formed according to Example 25 are tabulated in Table 60.
  • the dissolution profiles of Examples 24 and 25 were compared to marketed products having similar active strengths using a basket apparatus rotating at 100 rpm. One-thousand milliliters (1000 ml) of 0.1 N HCl solution was used as the dissolution medium.
  • Tables 61-63 show the results accelerated stability study of the tablets formed according to Example 24.
  • Table 64 shows the results accelerated stability study of the tablets formed according to Example 25.
  • the tablets were packaged in a high-density polyethylene (HDPE) container stored at a temperature of 40° C. ⁇ 2° C. and a relative humidity (RH) of 75% ⁇ 5%.
  • HDPE high-density polyethylene
  • Example 26-28 Ingredients corresponding to Examples 26-28 are tabulated in Table 65, with the amount of each ingredient given in respective percent by weight (% w/w).
  • the active ingredient is pimobendan.
  • the active strength of pimobendan is about 10 mg.
  • the results of a texture analysis of the tablets formed according to Example 28 are tabulated in Table 67.
  • the texture analysis was performed using a CT3 Texture Analyzer (Brookfield Engineering) using a TA18 Probe and twenty-five-thousand gram (25,000 g) load cell and five gram (5 g) trigger load, over four millimeters (4 mm) using two millimeter per second (2 mm/s) test speed and using a data rate of twenty (20) points/second.
  • Example 29 Ingredients corresponding to Example 29 are tabulated in Table 71, with the amount of each ingredient given in respective percent by weight (% w/w).
  • the active ingredient in Example 29 is ibuprofen.
  • Ibuprofen particles are coated with hydrophilic hydrogel coating creating effective taste barrier.
  • the active strength of ibuprofen is about 200 mg per unit. Because ibuprofen in Example 29 is coated with hydrophilic hydrogel coating, it has an average assay of about ninety-two (92) percent by weight (% w/w). That is, about 217.4 mg per unit of ibuprofen coated with hydrophilic hydrogel coating is incorporated to composition of Example 29.
  • Example 30 Ingredients corresponding to Example 30 are tabulated in Table 73, with the amount of each ingredient given in respective percent by weight (% w/w).
  • the active ingredient in Example 30 is acetaminophen.
  • Acetaminophen particles are coated with hydrophilic hydrogel coating creating effective taste barrier.
  • the active strength of acetaminophen is about 160 mg per unit. Because acetaminophen in Example 30 is coated with hydrophilic hydrogel coating, it has an average assay of about ninety-two (92) percent by weight (% w/w). That is, about 174 mg per unit of ibuprofen coated with hydrophilic hydrogel coating is incorporated to composition of Example 30.

Abstract

A product and process of manufacturing an edible soft-chewable dosage form for the delivery of pharmaceutically active ingredients or nutritional agents orally to an animal or human subject, by forming a granulated soft-chew mass by appropriate mixing and sifting steps, and forming tablets with a compression press. Such soft-chew dosage forms have hardness of less than about two kilopond (2 kp) and friability of less than about one percent (1%) at three-hundred (300) rotations when measured according to the United States Pharmacopeia (USP) test. The process for manufacturing such compressed soft-chew tablets employs compression (tablet) pressing equipment to produce soft-chew tablets of consistent weight and texture.

Description

    RELATED APPLICATIONS
  • The present application is a continuation-in-part of U.S. patent application Ser. No. 15/629,354 filed Jun. 21, 2017, entitled SOFT CHEW PHARMACEUTICAL FORMULATIONS, which is a continuation-in-part of International Patent Application No. PCT/US2016/067443 filed Dec. 19, 2016, entitled SOFT-CHEW TABLET PHARMACEUTICAL FORMULATIONS, which claims the benefit of U.S. Provisional Patent Application Ser. No. 62/269,951, filed Dec. 19, 2015, entitled SOFT CHEW TABLETS, each of which is hereby incorporated in its entirety by reference herein.
    • BACKGROUND 1. Field
  • The present invention relates to products and processes for the manufacture of soft-chewable tablet pharmaceutical or nutritional dosage forms, for the oral administration of active pharmaceutical ingredients or nutritional agents.
    • 2. Discussion of Prior Art
  • Chewable pharmaceutical dosage units, such as chewable tablets and soft-chewable tablets, are known and have been commercialized for use with pediatric, geriatric, and involuntary patient populations. Such dosage forms have also been used for subjects that, by instinct, will not accept the medication meant to be swallowed (e.g., animals). Chewable tablets are also useful with competent patients as an alternative to tablets or capsules that must be swallowed whole. The formulation of a drug into a chewable dosage form can increase patient acceptance of a medication in patients that resist or are unable to swallow conventional tablets or capsules.
  • Conventional dosage forms, such as chewable compressed tablets, using conventional ingredients, can make the tablet gritty or otherwise unappealing to many patients.
  • Traditionally, tablets compressed on a compression machine are formulated and processed so the tablets have hardness of more than ten kiloponds (10 kp). Tablets having lower hardness levels are discouraged in the prior art to keep the tablet friability acceptable.
  • A process for manufacturing soft-chewable dosage form for drug delivery is described in U.S. Pat. No. 6,387,381. It discloses a soft-chewable medication vehicle for drug delivery of an active ingredient to animal or human subjects, not containing ingredients of animal origin, without use of heat and without addition of water. The formed mixture was formed into individual chunks using a Formax F6™ molding machine with dies for production of chunk-like shapes, and packaged for storage.
  • Machines for the production of molded food patties have been described to be useful for the manufacturing of soft-chews for administration to non-human animals. Such machines are molding machines that have been originally developed for use in producing molded food products, for example the Formax F6™ molding machine made by the Formax Corporation.
  • The use of extruders, forming machines and rotary molding machines exhibit problems associated with the weight and physical forms of a final dosage form. Moreover, the use of such technologies may require conditioning of the final dosage form (e.g. drying or curing final formed structure) for consolidation of shape and structure of formed dosage form. Further, the use of such technologies, equipment and processes is complex, cumbersome, and not traditionally employed by typical pharmaceutical manufacturing facilities producing solid oral dosage forms.
  • Thus, there is a need for processes of manufacturing soft-chew tablet formulations on a large scale using commonly installed pharmaceutical manufacturing equipment such as a rotary (tablet) compression press.
    • SUMMARY OF THE INVENTION
  • The following brief summary is provided to indicate the nature of the subject matter disclosed herein. While certain aspects of the present invention are described below, the summary is not intended to limit the scope of the present invention.
  • The present invention overcomes the disadvantages and shortcomings of known chewable dosage forms by providing a simplified manufacturing process for soft-chewable dosage unit formulation comprising a highly palatable composition to patients, which is formed by conventional compression techniques using conventional pharmaceutical equipment, such as a rotary tablet press.
  • It has been found that many conventional soft-chew tablet formulations, made in the prior art using molding or extrusion techniques, can be manufactured more efficiently, reliably, and reproducibly, using a tablet press. The compressed soft-chew dosage forms of the current invention have hardness of less than 2 kp, or may have hardness of less than 1 kp, or may have no measurable hardness when tested with a conventional tablet hardness tester. Despite the low hardness, such compressed soft tablets have friability of less than 1.0%, or less than 0.5%, or less than 0.1% for 100 rotations (according to United States Pharmacopeia (USP) test <1216>); 200 rotations or 300 rotations.
  • Dosage forms of the present invention include palatable, soft-chewable pharmaceutical compositions for oral administration to an involuntary subject population (e.g., very young children, senile patients, animals, etc.) that includes a therapeutically effective amount of a pharmaceutically active ingredient susceptible to abuse, in an immediate or controlled release form, and a palatability improving agent in an amount sufficient make the pharmaceutical composition palatable to the subject population. As used herein, the phrase “involuntary subject population” is defined as patients who cannot be conventionally instructed to chew and/or swallow conventional hard chew tablets or capsules.
  • The texture of a chewable dosage unit form is an important factor in the acceptance of oral dosage forms by patients in need of medication. Soft-chewable tablet dosage units, having a soft texture, pleasant mouthfeel, and palatable taste with adequate flavoring agents, provide a solution to such problems. In addition, these features can address the problem of the disagreeable taste of many active pharmaceutical ingredients. Appropriate chewable dosage form can also address texture problems caused by dry dusty, granular, and pulverant properties of many pharmaceutical ingredients.
  • The soft-chewable formulations are prepared according to methods conventional in the art, such as wet or dry granulation processes.
  • A soft-chewable pharmaceutical dosage unit is a solid pharmaceutical dosage unit at room temperature that has low hardness and higher moisture content than a conventional tablet or hard chewable tablet. Such a dosage unit exhibits a plastic rheological behavior and can be formed by many manufacturing processes described in prior art into many different shapes. A soft-chewable pharmaceutical dosage unit after forming should be dimensionally stable. The ingredients of such a soft-chewable pharmaceutical dosage unit may be of pharmaceutical grade.
  • A semi plastic oral dosage form unit has a soft texture and hardness such that the unit is intended to be chewed and swallowed. The texture of the unit is such that it does not appreciably dissolve in the mouth.
  • This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the detailed description. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter. Other aspects and advantages of the present invention will be apparent from the following detailed description of the embodiments and the accompanying drawing figures.
    • BRIEF DESCRIPTION OF THE DRAWING FIGURES
  • A preferred embodiment of the present invention is described in detail below with reference to the attached drawing figures, wherein:
  • FIG. 1. is a plot of the texture characterization and comparison to marketed soft-chewable tablet for data in Example 1, showing load peaks applied at 2, 9, and 10 seconds;
  • FIG. 2. is a plot of the texture characterization and comparison to marketed soft-chewable tablet for data in Example 4, showing load peaks applied at 2, and 15 seconds;
  • FIG. 3. is a plot of the dissolution vs. time in 0.1 N HCl, USP II apparatus, 900 ml, 100 rpm for data in Tables 7 and 8;
  • FIG. 4. is a plot of the percent drug release vs. time in acetate buffer, USP II, 900 ml, 100 rpm for data in Tables 9 and 10;
  • FIG. 5. is a plot of the percent drug release vs. time in phosphate buffer, pH 7.5, USP II apparatus, 900 ml, 100 rpm for data in Tables 11 and 12;
  • FIG. 6. is a plot of the comparative dissolution of data in Tables 14 and 15, glycine buffer pH 3.0, USP II apparatus, 900 ml, 75 rpm; and
  • FIG. 7. is a plot of the percent drug release v/s time in citrate buffer pH 4.0, USP II apparatus, 900 ml, 100 rpm for data in Table 16.
    •
  • The drawing figures do not limit the present invention to the specific embodiments disclosed and described herein, with emphasis instead being placed upon clearly illustrating the principles of the preferred embodiment.
    • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The present invention is susceptible of embodiment in many different forms. While the figures show, and the specification describes, certain preferred embodiments of the invention, it is to be understood that such disclosure is by way of example only. There is no intent to limit the principles of the present invention to the particular disclosed embodiments.
  • The inventors have discovered that by formulation of a soft chew mass according to the present invention, conventional tablet compression techniques (such as a tablet press) can be used to form very soft tablets. Preferably, tablets of the present invention will have a uniform composition.
  • In certain embodiments of the present invention, dosage forms are formed by making a soft chew mass. The soft chew mass includes various excipients including lipid and dry ingredients, granulation ingredients (granulation aid ingredients and intra-granulation ingredients), extra-granulation ingredients, and active ingredients. During the granulation process, granules of the soft chew mass are formed, passed through appropriate screens for sizing, and then compressed using a rotary tablet press.
  • The solid, soft chewable or semi-plastic oral dosage forms of the present invention have a soft texture, low hardness, and may be chewed and swallowed. The texture of the unit is such that it does not appreciably dissolve in the mouth. Dosage forms of the present invention may be designed to be chewed and swallowed by a human or an animal.
  • A tablet press is a mechanical device that compresses powder into tablets of uniform size and weight. A press can be used to manufacture tablets/pellets of a wide variety of materials, including pharmaceuticals, cleaning products, and cosmetics. There are two types of press machines, eccentric-type and rotary-type. The rotary-type is generally more widely used, because it facilitates high production performance with narrow weight variation along with ease of use.
  • As used herein, the term “fluid” refers a material that is flowable or malleable. A fluid material may be a viscous liquid, with a viscosity comparable, for example, to water, vegetable oil, honey, or peanut butter.
  • One aspect of the present invention relates to a solid, soft chewable or semi-plastic oral dosage form system including at least one active ingredient. Preferably, the solid, soft chewable or semi-plastic oral dosage forms of the present invention are obtained by compression on a rotary tablet press. Preferably, the solid, soft chewable or semi-plastic oral dosage forms of the present invention exhibit a hardness of less than two kiloponds (2 kp) when measured on tablet hardness tester. More preferably, the solid, soft chewable or semi-plastic oral dosage forms of the present invention exhibit a hardness of less than one kilopond (1 kp) when measured on tablet hardness tester. Even more preferably, the solid, soft chewable or semi-plastic oral dosage forms of the present invention exhibit no hardness when measured on tablet hardness tester. Preferably, the solid, soft chewable or semi-plastic oral dosage forms of the present invention have a friability of less than about 1% at 100 rotations.
  • In one embodiment of the present invention, a soft-chew mass is formed by blending appropriate active ingredients and excipients. The soft-chew mass is compressed in tablet press to provide tablets with minimal hardness. Preferably, the tablets of the present invention have a hardness less than or equal to about two kiloponds (2 kp). More preferably, the tablets of the present invention have a hardness of less than or equal to about one kilopond (1 kp). Even more preferably, the tablets of the present invention have no measurable hardness in a tablet hardness testing apparatus.
  • In one embodiment of the present invention, a process is provided for the manufacture of a compressed soft-chew tablet unit dosage form for the oral administration of an active ingredient, in which a soft-chew tablet or semi-plastic tablet is formed by compressing a soft-chew mass on a compression press, and wherein the soft-chew tablets have a hardness of less than about two kiloponds (2 kp) and a friability of less than about one percent (1%) at three-hundred (300) rotations.
  • In certain embodiments of the present invention, a process is provided for the manufacture of a compressed soft-chew tablet unit dosage form for the oral administration of an active ingredient, in which a soft-chew mass mixture is provided including an active ingredient, wherein the soft-chew mass is a granulate (granules) formed with a granulation and sifting step, and wherein the soft-chew mass granulate is pressed into tablets using a tablet press, and wherein the soft-chew tablets have a hardness of less than about two kiloponds (2 kp) and a friability of less than about one percent (1%) at three-hundred (300) rotations.
  • In certain embodiments of the present invention, an edible compressed soft-chew tablet or semi plastic oral unit dosage form is manufactured by a process of: (a) mixing at least one active ingredient with at least one dry or liquid component to form a liquid premix; (b) blending dry ingredients having at least one of each of a bulking agent, a lipid, a flavoring agent, a disintegrating agent, a binding agent, a surfactant, a preservative, a lubricating agent, and an anti-sticking to form a uniform dry ingredient mixture; (c) blending the premix and the uniform dry ingredient mixture to form a granulated compacted soft-chew mass; (d) sifting the granulated compacted soft-chew mass through at least one sifting screen to form uniform granules of the soft-chew mass; and (e) adding a lubricant or anti sticking agent to the uniform granules of the soft-chew mass and compressing the resulting mixture in a tablet press to from soft-chew tablets.
  • In certain embodiments, two or more mixtures are prepared in the inventive process. A first mixture is a fluid premix containing the active ingredient, and a second mixture is a blend of dry ingredients. The fluid premix and dry ingredient blend may be blended together to form a soft-chew mass.
  • As used herein, the term “active ingredient” or “active agent” refers to an active pharmaceutical ingredient or nutritional agent.
  • An active pharmaceutical ingredient is a substance used in a pharmaceutical dosage form, intended to furnish pharmacological activity or to otherwise have direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to have direct effect in restoring, correcting or modifying physiological functions in a patient population (humans or animals).
  • A nutritional agent may include vitamins, minerals, glycosaminoglycan or its active members, amino acids or combination thereof that are useful in human or animal nutrition.
  • An active pharmaceutical ingredient may include any approved or experimental drug. By “approved,” it is meant that the drug is approved for human or veterinary use by a regulatory agency in any country that makes such drug approvals. For example, the pharmaceutically active ingredient may be selected from an anesthetic agent, anthelmintic agent, analgesic agent, steroid, corticosteroid agent, non-steroidal anti-inflammatory drug (NSAID) agent, antiemetic agent, anti-thyroidal agent, parasiticidal agent, appetite stimulant, antihistamine agent, antifungal agent, antiprotozoal agent, or anti-depressant.
  • In certain embodiments of the present invention, the active ingredient may be in granular form and coated, or further coated, with a suitable coating. For example, the coating could be a coating polymer that coats and protects the active ingredient, or masks an offensive taste and/or offensive odor. In certain embodiments, the coating could be a functional coating (e.g., an extended-release coating, delayed-release coating, controlled-release coating, barrier coating, or a combination thereof).
  • In certain embodiments of the present invention, the active ingredient may be dissolved, emulsified, or suspended in a non-aqueous solvent before addition. The nutritional or pharmaceutically active ingredient may be soluble, partially soluble, or insoluble in water.
  • In certain embodiments of the present invention, the active ingredient is added to the composition by dry blending.
  • In certain embodiments of the present invention, the active ingredient may be conjugated with other ingredients, such as cyclodextrins, surfactants, solubility or bioavailability enhancers, etc., to inhibit interactions with other excipients or with the environment, or to promote the chemical stability, improve solubility, enhance bioavailability, or improve the palatability of the nutritional ingredient or pharmaceutically active agent. Similarly, the pharmaceutically active ingredient may be incorporated into a novel drug delivery system, such as microspheres, microcapsules, liposomes, niosomes, nanoparticles, microemulsions, or nanoemulsions to protect the drug or permit organ targeting.
  • In certain embodiments of the present invention, the rate of release of the active ingredient may be modulated or controlled by, for example, the use of controlled or sustained release agents (e.g., polymers) or by using excipients (e.g., disintegrants) that promote in rapid release, as appropriate.
  • In certain embodiments of the present invention, a single excipient has more than one function in the formulation of the present invention. For example, propylene glycol and glycerol may be present and have a simultaneous role as a plasticizer, humectants, antimicrobial agents, or any combination of any two or more thereof, in this formulation. Lipids may have a role as a lubricant, plasticizer, binders, or any combination of any two or more thereof. Any suitable excipient may be used. Lipids may include, but are not limited to, mineral oils, liquid vegetable oils, or solid hydrogenated vegetable oils. Vegetable oils may include, but are not limited to, soybean oil, olive oil, flaxseed oil, canola oil, or corn oil.
  • In certain embodiments of the present invention, the active ingredient may be mixed with a lipid (e.g., vegetable oil) to form a premix.
  • In certain embodiments, the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes a texturing agent, selected from the group comprising of modified corn starches, polyols, poly(ethylene) oxide, microcrystalline cellulose co-processed with guar gum and the like. A polyol may include propylene glycol, glycerin, polyethylene glycol and mixtures thereof.
  • In certain embodiments, the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes one or more fillers. A filler may be used to increase the total mass of the chewable formulation to a manageable size or to enhance the flow properties of final powder or granules to be compressed in a rotary tablet press.
  • In certain embodiments, the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes a binding agent. The binding agent may be polyethylene glycol. The polyethylene glycol may be admixed to dry ingredients for mixing. The polyethylene glycol may be melted and added to at least one other dry ingredient and mixed to form the uniform dry ingredient mixture.
  • In certain embodiments, the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes microcrystalline cellulose as a bulking agent.
  • In certain embodiments, the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes lipid and microcrystalline cellulose in a ratio of about 2:1 to about 1:2.5, w/w, and wherein the tablet is manufactured by compression on a tablet press.
  • In certain embodiments of the present invention, one or more diluents may be used in combination with silicified microcrystalline cellulose. Examples of diluents include starches and their derivatives (e.g., hydrogenated starch hydrosylate), celluloses and their derivatives (e.g., cellulose acetate), protein matrices (soy protein, dextrates, wheat gluten, whey, corn cob, corn gluten), carbohydrates (e.g., maltodextrin, polydextrose), sugars and sugar alcohols (glucose, lactose, fructose, maltose, dextrose, sucrose, maltitol, xylitol, isomalt, mannitol), silicates, calcium phosphates, calcium sulfate, dextrates, kaolin, magnesium carbonate, polymethacrylates, talc, salts (e.g., sodium chloride) or any combination of any two or more thereof.
  • In certain embodiments, the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes a starch, or a modified starch, or a mixture of starch and a modified starch.
  • In certain embodiments of the present invention, diluents may also serve a role in fat or oil absorption, disintegration, and binding, providing nutrition, lubrication or any combination of any two or more thereof. The diluents may also be used for taste masking or modifying texture, for example microcrystalline cellulose co-processed with guar gum and/or modified corn starches.
  • In certain embodiments, the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes one or more binders. Binders improve the binding properties of the compacted mass, to assist the formation of compact dosage units. Any suitable binder known in the art may be used. For example, binders that may be used according to the present invention may include, but are not limited to gums (e.g., xanthan gum and guar gum), alginates, celluloses and their derivatives (e.g., methylcellulose and microcrystalline cellulose), lipids (e.g., fats and oils), starches and their derivatives, dextrins, povidones, silicates, polymethacrylates, polyethylene oxides, waxes, chitosan, polycarbophil, agar, carbomers, and combinations of the foregoing.
  • In certain embodiments, the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes one or more palatability enhancers. Palatability enhancers improve the taste of material that is chewed. Advantageously, palatability enhancers may improve the palatability of soft-chewable formulations comprising bitter, acrid, obnoxious, unpleasant, or otherwise unpalatable nutritional or pharmaceutically active agents.
  • In certain embodiments of the present invention, the palatability enhancer is a taste masking agent, a flavoring agent, an aroma modifier, or a taste modifier, or any combination of any two or more thereof.
  • Flavoring agents may be used to improve the palatability of the chewable tablets. Any type of flavoring agent can be used provided it improves the palatability of the product, typically by improving either its taste and/or smell. The use of a flavoring agent may also assist with dose compliance. Flavors can be natural (derived from animal or plant sources), semisynthetic, or artificial. In one embodiment, the flavoring agent is an artificial flavoring agent, semi-synthetic flavoring agent, a natural flavoring agent, or nature identical flavoring agent.
  • In certain embodiments, the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes liquid components that are absorbed on the surface of a lipid absorbing pharmaceutical ingredient selected from one or more of microcrystalline cellulose, silicified microcrystalline cellulose, and a combination of microcrystalline cellulose and guar gum. The liquid components absorbed on the surface of the lipid absorbing pharmaceutical ingredient may be mixed with the dry ingredient mixture and then sifted again through at least one sifting screen to form further granules of the soft-chew composition mixture. In an embodiment, a nutritional agent or a pharmaceutically active ingredient is admixed with the liquid components prior to mixing with the lipid absorbing pharmaceutical ingredient.
  • In certain embodiments of the present invention, plasticizers may be used to the formulation to improve plasticity and malleability of dosage units of the present invention. In one embodiment, a plasticizer may be selected from alcohols, glycols (such as propylene glycol), lanolin, wool fat, liquid paraffin, mineral oil, petrolatum, benzyl phenylformate, chlorobutanol, diethyl phthalate, glycerol, polyethylene glycol, propylene glycol, sorbitol, triacetin, benzyl phenyl formate, dibutyl sebacate, tributyl citrate, triethyl citrate, or any combination of any two or more thereof. Other plasticizers known in the art may also be used.
  • In certain embodiments, the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes a non-active ingredient including of one or more of a starch, a polysaccharide, a humectant, a polyol, water-soluble poly(ethylene oxide) resin.
  • In certain embodiments, the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes a humectant. A humectant is used to retain moisture in the dosage unit. A humectant of value in this invention may be selected from sodium and potassium chloride, benzalkonium chloride, aluminum silicate, sodium propionates, sodium and potassium phosphates, sugars, sulfites, hydrogenated starch hydrosylate, etc. Liquid humectants include, but are not limited to, glycols, polyols, sugar alcohols, vegetable oils and mineral oil, hydrogenated vegetable oils, hydrocarbons, triacetin, liquid paraffin, or any combination of any two or more thereof. Other humectants known in the art may also be used.
  • In certain embodiments, the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes an antioxidant. An antioxidant inhibits oxidation and may be of benefit as a preservative, or to maintain the chemical stability of an active or inactive ingredient. An antioxidant may be selected from propyl gallate, ascorbic acid and its derivatives, sodium formaldehyde sulfoxylate, malic acid, fumaric acid, editic acid, thiols, polyphenols, sodium EDT A, sodium ascorbate, sodium metabisulfite, butylated hydroxytoluene, butylated hydroxyanisole, butylated hydroxyanisole and butylated hydroxytoluene co-processed with zea mays oil or natural substances such as flavanoids, tocopherols, carotenes, cysteine, or any combination of any two or more thereof. Other antioxidants known in the art may also be used. The antioxidants are generally added to the formulation in amounts of from about one one-hundredth percent (0.01%) to about two percent (2.0%), based upon total weight of the formulation, with about one one-hundredth percent (0.01%) to about one percent (1.0%) being especially preferred.
  • In certain embodiments, the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes a preservative selected from the group including parabens (methylparaben and/or propylparaben), benzalkonium chloride, benzethonium chloride, benzoic acid, citric acid, fumaric acid, benzyl alcohol, bronopol, butylparaben, cetrimide, chlorhexidine, chlorobutanol, chlorocresol, cresol, ethylparaben, imidurea, methylparaben, phenol, phenoxyethanol, phenylethyl alcohol, potassium sorbate, sodium benzoate, sodium propionate, sorbic acid, thimerosal, and quaternary ammonium compounds. Other preservatives known in the art may also be used.
  • In certain embodiments, the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes a nonaqueous solvent, for example glycerin or sorbitol. A non-aqueous solvent may disperse, solubilize or enhance solubilization of the nutritional or pharmaceutically active agent. The non-aqueous solvent may also enhance the binding of the formulation and the consistency and texture of the soft-chewable dosage form.
  • In certain embodiments, the composition of the solid, soft chewable or semi-plastic oral dosage form of the present invention includes a disintegrating agent. A disintegrating agent may be used to enable the inventive chewable tablets to break down on contact with water, saliva, or gastric fluid in the stomach to quickly release the active ingredient. A disintegrating agent may be selected from povidones, croscarmellose sodium, sodium starch glycollate, celluloses and their derivatives, starches and their derivatives, gelatin, silicon dioxide, or any combination of any two or more thereof. Other disintegrating agents known in the art may also be used. Disintegration may be tested and measured using United States Pharmacopeia (USP) Disintegration Test <701> for uncoated tablets, using water as medium.
  • In certain embodiments of the present invention, a granulated compacted soft-chew mass is formed, and the mass is dried by equipment using direct or indirect conduction heat applied to a static solid bed, a moving solid bed, or a fluidized solid bed. The granulated mass may be dried at room temperature, for example about twenty-five degrees Celsius (25° C.) plus-or-minus ten degrees Celsius (10° C.). Alternatively, the granulated mass may be dried at a controlled temperature of about fifty degrees Celsius (50° C.) or less.
  • In certain embodiments of the present invention, the process of this invention may include sifting, or milling, of dry components or a granulated mass, or a mixture of both through sifting screens with mesh sizes commonly known in the art. Mesh sizes for sifting screens may include Mesh # 4 or 5 or 6 or 7 or 8 or 10 or 12 or 14 or 16 or 18 or 20 or 25 or 30 or 35 or 40 or 45 or 50 or 60 or other mesh sizes commonly known in the art. Components may be sifted through at two or more screens with different mesh sizes one after other in gradual or random order of mesh sizes.
  • In certain embodiments of the present invention, the dry ingredient mixture or the granulated compacted soft-chew mass is sifted through sifting equipment using impaction, attrition, compression or cutting.
  • In certain embodiments of the present invention, the dry ingredient mixture or the granulated compacted soft-chew mass is uniformly mixed using equipment using diffusion mixing, convection mixing or pneumatic mixing.
  • In certain embodiments of the present invention, the process of this invention may employ pre-compression force applied to the granulated compacted soft-chew mass before application of main compression force for compression of soft-chews.
  • In certain embodiments of the present invention, the granulated compacted soft-chew mass is fed into a compression die by gravity feed, power assisted feed, by centrifugal force, or by compression coating.
  • In certain embodiments of the present invention, the soft-chew tablets of this invention may incorporate an abuse-deterrent technology, which can include one or more of high-melting-point excipients that resist heating and injecting; taste modifiers that resist covert administration, snorting (ingestion of a powdered material through the nose) and dose dumping (extraction of active pharmaceutical ingredients (API) from tablets); water insoluble excipients that resist extraction and drink adulteration; waxy excipients that resist snorting; viscosity modifiers that resist dissolution, injection and dose dumping; low-density excipients that resist drink adulteration; and dyes, that resist adulteration.
  • The breaking force of tablets is commonly called hardness in the pharmaceutical literature. The term crushing strength is also frequently used to describe the resistance of tablets to the application of a compressive load.
  • The measure of the mechanical integrity of tablets is their breaking force or hardness, which is the force required to cause them to fail (i.e., break) in a specific plane. Various equipment is used for hardness measurements, for example a Monsanto Hardness Tester, Stokes Hardness tester, Pfizer Hardness Tester, Strong-Cobb Hardness Tester, or Schleuniger Hardness tester. Tablet hardness can be expressed using various units depending on the equipment used for hardness measurement. The units for tablet hardness measurement are newtons, pounds, Strong-Cobb units, and kiloponds.
  • For the hardness measurements for exemplarily examples in this invention, a Schleuniger Hardness tester was used, and hardness was measured in kiloponds or newtons. This apparatus has two parallel platens between which a tablet is placed. A load is applied and the value of the hardness is measured. The platen faces are polished smooth and precision-ground perpendicularly to the direction of movement. Perpendicularity is preserved during platen movement, and the mechanism is free of any bending or torsion displacements as the load is applied. The contact faces are larger than the area of contact with the tablet.
  • In one embodiment, the chewable formulation of this invention includes dosage units which have hardness of less than two kilopond (2 kp), preferably less than one kilopond (1 kp), and more preferably has no measurable hardness when measured with a tablet hardness tester.
  • In certain embodiments of the present invention, the chewable formulation of this invention includes dosage units with hardness less than three (3.0) Strong Cobb units, preferably less than one and one-half (1.5) Strong Cobb units, or more preferably no measurable hardness when measured with a tablet hardness tester.
  • In certain embodiments of the present invention, the chewable formulation of this invention includes dosage units with hardness less than five (5.0) pound, preferably less than two and one-half (2.5) pound, or more preferably no measurable hardness when measured with a tablet hardness tester.
  • In certain embodiments of the present invention, the chewable formulation of this invention includes dosage units with hardness less than twenty (20.0) newtons, preferably less than ten (10) newtons, or more preferably no measurable hardness when measured with a tablet hardness tester.
  • A friability value of about one percent (1%) or less (when measured as per USP test) is desirable for tablets in order for them to withstand the stress of handling during production, packaging, and transport.
  • In one embodiment the formulation comprises of dosage units with friability less than one percent (1%), preferably less than one-half percent (0.5%), or more preferably less than one-tenth percent (0.1%) for one-hundred (100) rotations (per USP), or two-hundred (200) rotations, or three-hundred (300) rotations.
  • For traditional tablet compression using rotary tablet press, tablet hardness is traditionally kept three kilopond (3 kp) or more. As dosage form size increases, compression force is increased to produce tablet with even higher hardness.
  • For tablets having hardness five kilopond (5 kp) or less, a high order of tablet rejection results because of stress during production, packaging, and transport. For such tablets tablet friability is generally between one-tenth percent (0.1%) and one percent (1.0%) when performed as per USP test.
  • As tablet hardness decreases, tablet friability generally increases. But the instant inventors have unexpectedly found that for exemplarily formulations herein, soft-chewable tablets with hardness less than two kilopond (2 kp) or lower, friability remains less than one percent (1%), preferably less than one-half percent (0.5%), more preferably less than one-tenth percent (0.1%) for one-hundred (100) rotations (per USP), two-hundred (200) rotations, or three-hundred (300) rotations.
  • In one embodiment, the soft-chewable tablet maintains a characteristic selected from chewiness, hardness, compression energy, adhesion, cohesiveness, springiness, and modulus, and any combination of any two or more thereof (when measured by the texture analyzer as per procedure for Example 1) sufficient to provide a chewable texture.
  • In one embodiment, the dosage unit of this invention (e.g., soft-chew) has a weight between about one-tenth gram (0.1 g) and about ten grams (10 g). In one embodiment, the dosage unit has a weight between about one-half gram (0.5 g) and about four grams (4.0 g). In one embodiment, the dosage unit has a weight between about one-tenth gram (0.1 g) and about three grams (3.0 g). In another embodiment, the weight of the dosage unit is between about one-tenth gram (0.1 g) and about two grams (2.0 g).
  • In certain embodiments of the present invention, weight of the dosage unit can be between about one-tenth gram (0.1 g) and about one gram (1.0 g); or between about one and one-tenth gram (1.1 g) and about two grams (2.0 g); or between about two and one-tenth grams (2.1 g) and about three grams (3.0 g); or between about three and one-tenth grams (3.1 g) and about four grams (4.0 g); or between about four and one-tenth grams (4.1 g) and about five grams (5.0 g).
  • In certain embodiments of the present invention, the dosage unit (e.g., soft-chew) of this invention can have an imprint on at least one surface of the dosage unit. In a specific embodiment this imprint can be on the top surface of the dosage unit. Such imprint can be, for example, letters, numbers, logos, or symbols, etc. An imprint can also be on the bottom surface.
  • In one embodiment, the dosage unit has a score or groove on one of the surfaces. This cross score has the effect that it facilitates the dividing of the dosage unit and allows more exact dosing of the active pharmaceutical ingredient according to the body weight, and/or age of the patient.
  • Such dosage units can have different weights, dimensions and shapes that can be adapted to the weight and need of the target patient population to allow accurate dosing. Dosage forms can be to different weights, dimensions and shapes known in the art. For example, the soft-chew tablets of this invention can be round, capsule-shaped, or have a modified shape.
  • The soft-chewable tablets of this invention can be packaged as bulk primary packaging, or as singular unit primary packaging.
    • EXAMPLES
  • The following Examples set forth preferred therapeutic agents and methods in accordance with the invention, but it is to be understood that these examples are given by way of illustration only, and nothing therein should be taken as a limitation upon the overall scope of the invention.
  • Ingredients corresponding to Example 1 are tabulated in Table 1, with the amount of each ingredient given in respective percent by weight (% w/w).
  • TABLE 1
    Ingredients % w/w
    Active
    Placebo Active 3.00
    Granulation Aid Ingredients
    Soybean Oil 15.00
    Zea Mays (corn) Oil & butylated 0.10
    hydroxyanisole (BHA) & butylated
    hydroxy toluene (BHT)
    Glycerin 19.00
    Intra-granular Ingredients
    Microcrystalline Cellulose 21.00
    Pregelatinized Corn Starch 5.00
    Extra-granular Ingredients
    Pregelatinized Corn Starch 3.00
    Beef Flavor 19.00
    Sodium Lauryl Sulfate 0.20
    Poly(ethylene) Oxide 1.00
    Maltodextrin 3.00
    Modified Corn Starch 3.00
    Crosscarmellose Sodium 3.70
    Color 0.01
    Polyethylene Glycol 3350 2.00
    Flow Aid Ingredients
    Magnesium Stearate 1.00
    Colloidal Silicon Dioxide 1.00
    Total 100
    • Procedure—Example 1
      • Step 1: Two methods were employed using the formulation summarized in Table 1. In the first method, a placebo active was added as part of granulation aid components, and in the second method placebo active was added as part of extra-granular addition, remaining procedure was same for both methods.
      • Step 2: The intra-granular ingredients and the active were passed through a sifting screen followed by uniform mixing.
      • Step 3: The extra-granular ingredients were passed through a sifting screen followed by uniform mixing.
      • Step 4: Granulation aid components were added to the intra-granular blend and mixed thoroughly until uniformly mixed, followed by melting polyethylene glycol 3350 and quickly adding this to granulated mass, followed by uniform mixing.
      • Step 5: The granulated mass from Step 4 was passed through a sifting screen to form uniform granules.
      • Step 6: The extra-granular blend from Step 3 was added to screened granules from step 5, followed by uniform mixing.
      • Step 7: Blended granules from Step 6 were passed through a sifting screen.
      • Step 8: Magnesium stearate and colloidal silicon dioxide mixed with small amount of granules from Step 6 and passed sifting screen.
      • Step 9: The milled (sifted) components from Step 8 were added to granules from Step 6 followed by uniform mixing followed by compressing on a rotary tablet press using 18 mm×18 mm rounded square punch.
  • Texture Analysis was performed using CT3 Texture Analyzer (Brookfield Engineering) using a TA3/100 probe and twenty-five-thousand gram (25,000 g) load cell and five gram (5 g) trigger load, over four millimeters (4 mm) using two millimeter per second (2 mm/s) test speed and using a data rate of one-hundred (100) points/second. Load peaks were applied at two (2), nine (9), and ten (10) seconds. The results are plotted in FIG. 1.
  • The results of a tablet characterization study are tabulated in Tables 2 and 3. In the study, tablets formed in accordance with Example 1 were compared to a marketed soft-chewable tablet. The marketed soft-chewable tablet was formed using an unconventional molding method. The data in Table 3 was obtained using a CT3 Texture Analyzer.
  • TABLE 2
    Marketed
    Parameters Product Example 1
    Weight (grams) 3.600-3.750 3000
    Shape Trapezoidal Square
    Color Multiple Strengths Yellowish Brown
    with Different Colors
    Width × Length 16.10 × 17.40 18 × 18
    Top (mm)
    Width × Length 17.80 × 18.60 18 × 18
    Bottom (mm)
    Thickness (mm)  9.20-9.60 8.00-9.00
    Disintegration Time   20-26 10 to 15
    (minutes)
    Tablet Hardness (kp) 0   0
    Tablet Friability (%) 0   0
  • TABLE 3
    Marketed
    Parameters Product Example 1
    Hardness  3000-3900 3698.00-3866.00
    (grams)
    Deformation at  3.95-4.00   1.78-3.58
    Hardness (mm)
    Adhesiveness 0.00 mJ-0.20 mJ 0.00 mJ-0.10 mJ
    Cohesiveness  0.30-0.34   0.00-0.15
    Gumminess 1100.00 g-1450.00 g 4.00 g-546.00 g
    Chewiness 24.40 mJ-93.70 mJ 0.00 mJ-42.70 mJ
  • Ingredients corresponding to Example 2 (a conventional hard chewable tablet) are tabulated in Table 4, with the amount of each ingredient given in respective percent by weight (% w/w).
  • TABLE 4
    Ingredients % w/w
    Step
    1 Ingredients
    Carprofen 5.00
    Artificial Beef Flavor 20.00
    Silicified Microcrystalline 17.95
    Cellulose
    Polycarbophil 2.50
    Polyethylene Glycol 3350 6.00
    Microcrystalline Cellulose & 3.00
    Guar Gum
    Pregelatinized Corn Starch 24.00
    Lactose Monohydrate 15.00
    Crosscarmellose Sodium 2.50
    Step 2 Ingredients
    Color
    1 0.03
    Color 2 0.02
    Talc 2.00
    Magnesium Stearate 2.00
    Total 100
    • Procedure—Example 2
      • Step 1: All step 1 ingredients were individually weighed and passed through a sifting screen and uniformly mixed.
      • Step 2: The step 2 ingredients were mixed along with small quantity of pre-mix from Step 1.
      • Step 3: The ingredients from Step 2 were added to the remaining pre-mixed ingredients from Step 1 and mixed for uniform mixing for 2-3 minutes and further subjected to compression on rotary tablet press for 500 mg fill weight.
  • Ingredients corresponding to Examples 3 and 4 are tabulated in Table 5, with the amount of each ingredient given in respective percent by weight (% w/w).
  • TABLE 5
    Example Example
    Ingredients 3 4
    Active
    Carprofen 0.84 3.34
    Granulation Aid Ingredients
    Soybean Oil 16.00 9.00
    Zea Mays Oil & BHA & 0.10 0.10
    BHT
    Glycerin 20.00 13.00
    Polyethylene Glycol 600 — 9.00
    Povicone K 30 2.00 2.00
    Intra-granular Ingredients
    Polycarbophil 0.30 —
    Silicified Microcrystalline 16.06 18.66
    Cellulose
    Pregrelatinized Corn Starch 7.00 7.00
    Calcium Sulfate Dihydrate 1.30 2.50
    Artificial Beef Flavor 8.00 15.00
    Crosscarmellose Sodium 2.5 2.5
    Polyethylene Glycol 600 — —
    Polyethylene Glycol 3350 2
    Extra-granular Ingredients
    Pregelatinized Corn Starch 4 5
    Artificial Beef Flavor 10 3
    Sodium Lauryl Sulfate 0.2 0.2
    Poly(ethylene) Oxide 1 1
    Modified Corn Starch 3 —
    Crosscarmellose Sodium 2.5 2.5
    Calcium Sulfate Dihydrate 1.7 1.7
    Lactose Monohydrate 1.5 4.5
    Total 100 100
    • Procedure—Example 3
      • Step 1: The active, soybean oil and Zea Mays Oil and BHA and BHT are weighed accurately and uniformly mixed to form a dispersion.
      • Step 2: Simultaneously, a dispersion was prepared by adding povidone to glycerin and properly mixing.
      • Step 3: Intra granular dry ingredients were passed through a sifting screen followed by uniform mixing.
      • Step 4: Dispersions from Step 1 and Step 2 were used as granulation aid, adding them one after another to pre-mixed ingredients from Step 3.
      • Step 5: The formed doughy mass was passed through a sifting screen to get wet granules.
      • Step 6: Extra-granular ingredients were passed through a sifting screen followed by uniform mixing.
      • Step 7: Approximately half the quantity of the extra-granular blend from Step 6 was added to the wet granules formed in Step 5 and uniformly mixed.
      • Step 8: The formed slightly dry granular mass was further passed through sifting screen to obtain granules.
      • Step 9: The formed granules are uniformly mixed with remaining quantity of extra granular blend from Step 6 and further subjected to compression on rotary tablet press using 18 mm×18 mm rounded square punch for 3.0 gram target fill weight.
    Procedure—Example 4
      • Step 1: Active, soybean oil and Zea Mays Oil and BHA and BHT are weighed accurately and uniformly mixed to form a dispersion.
      • Step 2: Simultaneously, a dispersion was prepared by adding Povidone and Polyethylene Glycol 600 to Glycerin and properly mixing.
      • Step 3: The Intra-granular dry ingredients were mixed together and passed through a sifting screen.
      • Step 4: The extra-granular dry ingredients were mixed together and passed through a sifting screen.
      • Step 5: The pre-mix from step 3 was added to a Rapid Mixer Granulator (RMG) bowl of appropriate size and mixed for 2 minutes with 60 rpm impeller speed.
      • Step 6: The Dispersion from step 1 was added slowly in about 1 minute and mixed further for 4 minutes with 60 rpm impeller speed and 150 rpm chopper speed.
      • Step 7: The dispersion from step 2 was added slowly in about 2 minute with 50 rpm impeller speed and 150 rpm chopper speed.
      • Step 8: The formed doughy mass was passed through a sifting screen to get wet granules.
      • Step 9: Approximately half the quantity of the extra-granular blend from step 4 was added to the wet granules formed in step 8 and uniformly blended.
      • Step 10: The formed slightly dry granular mass was further passed through a sifting screen to get granules.
      • Step 11: The formed granules had a Loss on Drying (LOD) value of 7.76% w/w at one-hundred-five degrees Celsius (105° C.) over a period of nine (9) minutes and thirty-seven (37) seconds.
      • Step 12: The formed granules are uniformly mixed with the remaining quantity of the extra-granular blend from step 4 and further subjected to compression on rotary tablet press using 18 mm×18 mm rounded square punch for three gram (3 g) target fill weight.
      • Step 13: The compressed tablets exhibited tablets hardness of zero (0) newton or kilopond when measured using conventional hardness tester and had tablet friability of 0.02% w/w.
  • Texture analysis was performed using CT3 Texture Analyzer using TA/RT/KIT probe and 25,000 g load cell and 510 g trigger load, over 4 mm using 2 mm/s test speed and using data rate of 10 points/second. Load peaks were applied at 2 and 15 seconds. The results are plotted in FIG. 2.
  • Table 6—Tablet Characterization, Examples 2-4
  • TABLE 6
    Test Parameters Example 2 Example 3 Example 4
    Weight (g) 0.500 3.0 3.0
    Shape Square Square Square
    Color Light Brown Yellow-Brown Yellow-Brown
    Dimension (mm) — 18 X 18 18 X 18
    Thickness (mm)  4.00-5.00   7.00-8.00   8.00-9.00 
    Disintegration Time (min) — 10.00-15.00 20.00-21.00
    Tablet Hardness (kp) 16.00-18.00 0 0
    Tablet Hardness (N) 170 — 0
    Tablet Friability (% w/w) — 0 0.02
    LOD at 105° C. (% w/w)  6.00-7.00  —  7.00-8.00 
  • The results of a comparative dissolution study (in vitro analysis—multimedia dissolution testing) involving the tablets formed according to Examples 2 and 3 are tabulated in Tables 7 and 8, respectfully. The dissolution profiles of Examples 2 and 3 were compared to a reference drug and a marketed soft-chew, respectfully. A paddle apparatus (USP II Apparatus) rotating at 100 rpm was used. The dissolution medium consisted of a nine-hundred milliliter (900 ml) 0.1 M HCl solution.
  • TABLE 7
    Time Points Reference Drug Example 2
    (Minutes) (Hard Chew) (Hard Chew)
    5 4.2 5
    15 8.8 10
    30 9.4 15
    45 9.9 13
    60 11.6 13
    90 11.9 18
    120 12.7 15
  • TABLE 8
    Example 3
    Time Points Marketed (Prototype
    (Minutes) Soft-Chew Soft-Chew)
    5 17 12.5
    15 28 24.0
    30 33 32.0
    45 37 32.1
    60 34 33.2
    90 35 30.5
    120 36 30.6
  • The data in Tables 7 and 8 is presented graphically in FIG. 3.
  • The results of a comparative dissolution study (in vitro analysis—multimedia dissolution testing) involving the tablets formed according to Examples 2 and 3 are tabulated in Tables 9 and 10, respectfully. The dissolution profiles of Examples 2 and 3 were compared to a reference drug and a marketed soft-chew, respectfully. A paddle apparatus (USP II Apparatus) rotating at 100 rpm was used. The dissolution medium consisted of a nine-hundred milliliter (900 ml) acetate buffer solution, pH 4.5.
  • TABLE 9
    Time Points Reference Drug Example 2
    (Minutes) (Hard Chew) (Hard Chew)
    5 5.8 13
    15 14.5 24
    30 19.4 32
    45 21.2 33
    60 24.0 33
    90 25.5 34
    120 25.5 34
  • TABLE 10
    Example 3
    Time Points Marketed (Prototype
    (Minutes) Soft-Chew Soft-Chew)
    5 21 18.0
    15 41 37.5
    30 53 51.4
    45 55 54.4
    60 56 54.1
    90 56 51.5
    120 57 53.0
  • The data in Tables 9 and 10 is presented graphically in FIG. 4.
  • The results of a comparative dissolution study (in vitro analysis—multimedia dissolution testing) involving the tablets formed according to Examples 2 and 3 are tabulated in Tables 11 and 12, respectfully. The dissolution profiles of Examples 2 and 3 were compared to a reference drug and a marketed soft-chew, respectfully. A paddle apparatus (USP II Apparatus) rotating at 100 rpm was used. The dissolution medium consisted of a nine-hundred milliliter (900 ml) phosphate buffer solution, pH 7.5.
  • TABLE 11
    Time Points Reference Drug Example 2
    (Minutes) (Hard Chew) (Hard Chew)
    5 23.8 26.00
    15 59.2 68.00
    30 90.8 92.00
    45 93.2 92.00
    60 93.6 92.00
    90 93.7 92.00
    120 94.1 93.00
  • TABLE 12
    Example 3
    Time Points Marketed (Prototype
    (Minutes) Soft-Chew Soft-Chew)
    5 25.0 22.0
    15 66.9 55.0
    30 91.1 87.0
    45 95.3 96.0
    60 95.3 97.0
    90 95.3 97.0
    120 95.3 97.0
  • The data in Tables 11 and 12 is plotted in FIG. 5.
  • Ingredients corresponding to Examples 5-8 are tabulated in Table 13, with the amount of each ingredient given in respective percent by weight (% w/w).
  • TABLE 13
    Exam- Exam- Exam- Exam-
    ple ple ple ple
    Ingredients 5 6 7 8
    Active
    Cefpodoxime Proxetil 13.50 — — —
    Enrofloxacin — 4.54 — —
    Pimobendan — — 0.08 —
    Deracoxib — — — 3.34
    Granulation Aid Ingredients
    Soybean Oil 7.00 9.00 10.00 15.00
    Zea Mays Oil & BHA & BHT 0.10 0.10 0.10 0.10
    Glycerin 20.00 13.00 12.00 19.50
    Polyethylene Glycol 600 3.00 9.00 10.20 —
    Povidone K 30 2.00 2.00 2.00 2.00
    Color — — 0.01 0.02
    Intra-granular Ingredients
    Polycarbophil — — — 0.25
    Lactose Monohydrate — — — —
    Sodium Carboxymethylcellulose 20.00 — — —
    Silicified Microcrystalline 3.85 18.15 18.71 15.59
    Cellulose
    Sodium Lauryl Sulfate 1.50 — — —
    Pregelatinized Corn Starch 2.00 7.00 7.00 8.00
    Calcium Sulfate Dihydrate — 2.50 2.50 2.50
    Artificial Beef Flavor 15.00 15.00 15.00 15.00
    Crosscarmellose Sodium 2.00 3.50 — 1.50
    Polyethylene Glycol 600 — — 2.50 1.00
    Color — — — —
    Polyethylene Glycol 3350 — — — —
    Extra-granular Ingredients
    Pregelatinized Corn Starch — 4.00 5.00 5.00
    Artificial Beef Flavor 3.00 3.00 3.00 3.00
    Citric Acid — — — —
    Sodium Carboxymethylcellulose 5.00 — — —
    Sodium Lauryl Sulfate — 0.20 0.30 0.20
    Poly(ethylene) Oxide — 1.00 1.00 1.00
    Color 0.05 — — —
    Modified Corn Starch — — — —
    Crosscarmellose Sodium 2.00 1.50 2.50 5.00
    Calcium Sulfate Dihydrate — 2.01 1.70 1.00
    Lactose Monohydrate- — 4.50 6.50 1.00
    Total 100.00 100.00 100.00 100.00
    • Procedure—Example 5
      • Step 1: Soybean oil and zea mays oil and BHA and BHT are weighed accurately and uniformly mixed to form a dispersion.
      • Step 2: Simultaneously, a dispersion is prepared by adding polyethylene glycol 600 to glycerin and properly mixing.
      • Step 3: Cefpodoxime proxetil (active) was part of the intra-granular addition. All intra-granular dry ingredients were mixed uniformly and passed through sifting screen.
      • Step 4: The dispersions from Step 1 and Step 2 are used as granulation aid, adding them one after another to the pre-mixed ingredients from Step 3.
      • Step 5: The formed doughy mass was passed through a sifting screen to get wet granules.
      • Step 6: The extra-granular ingredients were mixed uniformly and passed through a sifting screen.
      • Step 7: Approximately half the quantity of the extra-granular blend from Step 6 was added to the wet granules formed in Step 5 and mixed uniformly.
      • Step 8: The formed slightly dry granular mass was passed through sifting screen to get granules.
      • Step 9: The formed granules were mixed uniformly with remaining quantity of extra-granular blend and further subjected to compression on rotary tablet press using 15.3 mm×15.3 mm rounded square punch for 2000 mg fill weight and 12.3 mm×12.3 mm rounded square for 1000 mg fill weight separately.
  • The results of a comparative dissolution study (in vitro analysis—multimedia dissolution testing) involving the tablets formed according to Example 5 are tabulated in Tables 14 and 15. The dissolution profile of Example 5 was compared to a reference drug. A paddle apparatus (USP II Apparatus) rotating at 75 rpm was used. The dissolution medium consisted of a nine-hundred milliliter (900 ml) glycine buffer solution, pH 3.0.
  • TABLE 14
    Reference Drug Example 5
    Time Points 100 mg 1000 mg
    (Minutes) (Hard Chew) (Soft-Chew)
    5 79.8 50.8
    15 99.9 95.8
    30 102.2 103.3
    45 101.0 104.8
  • TABLE 15
    Reference Drug Example 5
    Time Points 200 mg 2000 mg
    (Minutes) (Hard Chew) (Soft-Chew)
    5 77.1 43.2
    15 92.3 86.4
    30 98.0 99.0
    45 98.4 103.0
  • The data in Tables 14 and 15 is plotted in FIG. 6.
    • Procedure—Examples 6-8
      • Step 1: The active, soybean oil and zea mays oil and BHA and BHT were uniformly mixed to form a dispersion.
      • Step 2: Simultaneously, a dispersion was prepared by weighing the remaining granulation aid ingredients followed by properly mixing.
      • Step 3: Intra granular dry ingredients were uniformly mixed and passed through a sifting screen.
      • Step 4: The dispersions from Step 1 and Step 2 were used as a granulation aid, adding them one after another to pre-mixed ingredients from Step 3.
      • Step 5: The formed mass was passed through sifting screens to get wet granules.
      • Step 6: The extra-granular ingredients were mixed uniformly and passed through a sifting screen.
      • Step 7: Approximately half the quantity of the extra-granular blend from Step 6 was added to the wet granules formed in Step 5 and mixed uniformly.
      • Step 8: The formed slightly dry granular mass was passed through a sifting screen to obtain granules.
      • Step 9: The formed granules are uniformly mixed with remaining quantity of extra-granular blend and further subjected to compression on rotary tablet press.
  • The results of a comparative dissolution study (in vitro analysis—multimedia dissolution testing) involving the tablets formed according to Example 6 are tabulated in Table 16. The dissolution profile of Example 6 was compared to a reference drug. A paddle apparatus (USP II Apparatus) rotating at 100 rpm was used. The dissolution medium consisted of a nine-hundred milliliter (900 ml) citrate buffer solution, pH 4.0.
  • TABLE 16
    Time Points Reference Drug Example 6
    (Minutes) (Hard Chew) (Soft-Chew)
    5 64.9 95.2
    10 96.9 97.2
    15 98.7 97.7
    30 99.2 96.6
    45 98.8 98.6
  • The data in Table 16 is plotted in FIG. 7.
  • Ingredients corresponding to Examples 9-11 (carprofen soft chewable tablets) are tabulated in Table 12, with the amount of each ingredient given in respective percent by weight (w/w %). In each of the Examples 9-11, the active ingredient is carprofen. In Example 9, the active strength of carprofen is about 25 mg. In Example 10, the active strength of carprofen is about 75 mg. In Example 11, the active strength of carprofen is about 100 mg.
  • TABLE 17
    Example Example Example
    Ingredient 9 10 11
    Granulation Aid
    Carprofen 0.83 2.5 3.33
    Mineral Oil 8 8 8
    Sorbitol 15.5 15.5 15.5
    Polyethylene Glycol (PEG-600) 6 6 6
    Povidone (K-30) 2.3 2.3 2.3
    Brown Iron Oxide 0.01 0.01 0.01
    Intra-granular Ingredients
    Carnauba Wax
    5 4 4
    Silicified Microcrystalline Cellulose 19.84 19.84 19.01
    Lactose 3.92 3 3
    Pregelatinized Corn Starch 2 2 2
    Calcium Sulfate Dihydrate 2 2 2
    Croscarmellose sodium 0.1 0.35 0.35
    Beef Flavor 15 15 15
    Extra-granular Ingredients
    Pregelatinized Corn Starch 5 5 5
    Silicified Microcrystalline Cellulose 7.5 7.5 7.5
    Beef Flavor 3 3 3
    Lactose 2 2 2
    Flow Aid Ingredient
    Sodium Stearyl Fumarate 2 2 2
    Total 100 100 100
    • Procedure—Examples 9-11
      • Step 1: All intra-granular materials (silicified microcrystalline cellulose, carnauba wax, pregelatinized starch, beef flavor, croscarmellose sodium, calcium sulfate dihydrate) were passed through simultaneously through #40 mesh screen using mechanical sifter and once again passed through #40 mesh screen.
      • Step 2: All extra-granular materials (pregelatinized starch, lactose monohydrate, beef flavor and croscarmellose sodium) passed through simultaneously through #40 mesh screen and once again passed through #40 mesh screen and approximately divided into two parts (75% and 25%).
      • Step 3: Sodium stearyl fumarate passed through #40 mesh screen and once again passed through #40 mesh screen.
      • Step 4: Sorbitol and polyethylene glycol kept in a vessel under stirring.
      • Step 5: Povidone was added to materials from Step 4 under continuous stirring to obtain a clear, lump free dispersion.
      • Step 6: Brown iron oxide added to materials from Step 5 under continuous stirring to obtain a lump free dispersion.
      • Step 7: Carprofen was added to mineral oil under continuous stirring to obtain a lump free dispersion.
      • Step 8: Dispersion from Step 7 was added to materials from Step 1.
      • Step 9: Dispersion from Step 6 was added to materials Step 8 to form a wet mass.
      • Step 10: Wet mass of Step 9 was kneaded for up to two (2) minutes.
      • Step 11: Wet mass of Step 10 and approximately 75% materials of Step 2 were passed through cone-mill using six millimeter (6 mm) screen at slow speed and knife forward to form granules.
      • Step 12: Granules from Step 11 were further passed through #8 mesh screen to form final granules.
      • Step 13: Granules from Step 12 and remaining 25% material from Step 2 were blended together for three (3) minutes.
      • Step 14: Granules from Step 13 were lubricated with material from Step 3 for five (5) minutes.
      • Step 15: The formed granules were subjected to compression on rotary tablet press using 18 mm×18 mm rounded square punch.
    Table 18: Tablet Characterization—Examples 9-11 Compared to Marketed Product
  • TABLE 18
    Marketed
    Parameters Product Example 9 Example 10 Example 11
    Weight (mg) 3860 3000 3000 3000
    Shape Trapezoidal Rounded Rounded Rounded
    Square Square Square
    Color Brown Light brown Light brown Light brown
    to brown to brown to brown
    Width × Length 16.4 × 17.1 18.0 × 18.0 18.0 × 18.0 18.0 × 18.0
    Top (mm)
    Width × Length 17.8 × 18.6 18.0 × 18.0 18.0 × 18.0 18.0 × 18.0
    Bottom (mm)
    Thickness (mm) 9.5 8.6 8.8 8.8
    Disintegration 26 20 24 26
    Time (min)
    Hardness (N) 0 0 0 0
    Friability (%) 0 0 0 0
    • Table 19: Texture Analysis—Examples 9-11 Compared to Marketed Product
  • Analysis performed using a CT3 Texture Analyzer (Brookfield Engineering) using a TA18 Probe and twenty-five-thousand gram (25,000 g) load cell and five gram (5 g) trigger load, over four millimeters (4 mm) using two millimeter per second (2 mm/s) test speed and using a data rate of twenty (20) points/second.
  • TABLE 19
    Marketed Example Example Example
    Parameters Product 9 10 11
    Hardness Cycle 1 5886 636 2088 1806
    (g)
    Hardness Cycle 2 4610 130 202 414
    (g)
    Deformation at 3.97 1.69 2.16 2.27
    hardness (mm)
    Stringiness Length 0.91 56.14 0.1 0
    (mm)
    Adhesiveness (mJ) 0.1 0.4 0.7 0
    Cohesiveness 0.46 0.02 0.03 0.41
    Gumminess (g) 2703 10 59 744
    Chewiness (mJ) 74.7 0.2 1.7 355.5
    Springiness 2.82 2.23 2.87 48.71
  • The results of a comparative dissolution study involving the tablets formed according to Examples 9-11 are tabulated in Tables 20-22, respectively. The dissolution profiles of Examples 9-11 were compared to marketed products having similar active strengths. A paddle apparatus rotating at 100 rpm was used. Nine-hundred milliliters (900 ml) of phosphate buffer pH 7.5 was used as the dissolution medium.
  • TABLE 20
    Marketed
    product Example
    Time point
    25 mg 9
    0 0 0
    5 20 27
    15 55 67
    30 89 90
    45 98 96
    60 98 98
    90 98 98
    120 98 98
  • TABLE 21
    Marketed
    product Example
    Time point 75 mg 10
    0 0 0
    5 16 19
    15 44 51
    30 76 77
    45 88 91
    60 93 96
    90 93 98
    120 93 98
  • TABLE 22
    Marketed
    product Example
    Time point
    100 mg 11
    0 0 0
    5 14 16
    15 42 45
    30 73 71
    45 89 87
    60 91 93
    90 92 97
    120 92 97
  • Ingredients corresponding to Examples 12-14 (carprofen soft chewable tablets) are tabulated in Table 23, with the amount of each ingredient given in respective percent by weight (% w/w). In each of the Examples 12-14, the active ingredient is carprofen. In Example 12, the active strength of carprofen is about 25 mg. In Example 13, the active strength of carprofen is about 75 mg. In Example 14, the active strength of carprofen is about 100 mg.
  • TABLE 23
    Example Example Example
    Ingredients
    12 13 14
    Granulation Aid Ingredients
    Mineral Oil
    8 8 8
    Sorbitol 15.5 15.5 15.5
    Polyethylene Glycol (PEG 600) 3.5 3.5 4
    Povidone (K-30) 0.5 0.2 0.4
    Brown Iron Oxide 0.01 0.01 0.01
    Intra-granular Ingredients
    Carprofen 0.83 2.5 3.33
    Carnauba wax 4 4 4
    Lactose 20.31 20.09 17.41
    Silicified Microcrystalline Cellulose 7.6 7.6 7.6
    Pregelatinized Corn Starch 2 2 2
    Calcium Sulfate Dihydrate 2 2 2
    Croscarmellose Sodium 0.25 0.6 0.25
    Beef Flavor 15 15 15
    Extra-granular Ingredients
    Pregelatinized Corn Starch 5 5 5
    Silicified Microcrystalline Cellulose 7.5 7 7.5
    Beef Flavor 3 3 3
    Lactose 3 2 3
    Flow Aid Ingredient
    Sodium Stearyl Fumarate 2 2 2
    Total 100 100 100
    • Procedure—Examples 12-14
      • Step 1: All intra-granular materials (carprofen, carnauba wax, lactose monohydrate, silicified microcrystalline cellulose, pregelatinized starch, calcium sulphate dihydrate, beef flavor and croscarmellose sodium) were passed simultaneously through #40 mesh followed by mixing.
      • Step 2: All extra-granular materials (lactose monohydrate, silicified microcrystalline cellulose, pregelatinized starch and beef flavor) were passed simultaneously through #40 mesh screen and approximately divided into two parts (75% and 25%).
      • Step 3: Sodium stearyl fumarate was passed through #40 mesh screen.
      • Step 4: Povidone was added to sorbitol and polyethylene glycol under continuous stirring to get clear solution.
      • Step 5: Brown iron oxide was added to dispersion from Step 4 under continuous stirring.
      • Step 6: Materials from Step 4 were added to the materials from Step 1 and mixed continuously until uniformly mixed, followed by addition of mineral oil and mixing continuously to get granulated wet mass.
      • Step 7: Wet mass from Step 6 was passed through multi-mill using six millimeter (6 mm) screen to form granules.
      • Step 8: 75% of the quantity of extra-granular materials from Step 2 and granules from Step 8 were passed through #8 mesh screen.
      • Step 9: Remaining quantity of extra-granular materials (25%) from Step 2 and granules from Step 9 were blended together for two (2) minutes.
      • Step 10: Sodium stearyl fumarate from Step 3 was added to granules from Step 10 and blended together for two (2) minutes.
      • Step 11: The formed granules from Step 10 were subjected to compression on rotary tablet press using 18 mm×18 mm rounded square punch.
    Table 24: Tablet Characterization—Examples 12-14
  • TABLE 24
    Example Example Example
    Parameters
    12 13 14
    Weight (mg) 3000 3000 3000
    Shape Rounded Rounded Rounded
    Square Square Square
    Color Light brown Light brown Light brown
    to brown to brown to brown
    Width × Length 18.0 × 18.0 18.0 × 18.0 18.0 × 18.0
    Top (mm)
    Width × Length 18.0 × 18.0 18.0 × 18.0 18.0 × 18.0
    Bottom (mm)
    Thickness (mm) 8.6 8.7 8.8
    Disintegration 20 18 25
    Time (min)
    Hardness (N) 0 0 0
    Friability (%) 0 0 0
  • The results of a texture analysis of the tablets formed according to Examples 12-14 are tabulated in Table 25. The texture analysis was performed using a CT3 Texture Analyzer (Brookfield Engineering) using a TA18 Probe and twenty-five-thousand gram (25,000 g) load cell and five gram (5 g) trigger load, over four millimeters (4 mm) using two millimeter per second (2 mm/s) test speed and using a data rate of twenty (20) points/second.
  • TABLE 25
    Example Example Example
    Parameters
    12 13 14
    Hardness Cycle 1 (g) 1310 1900 1434
    Hardness Cycle 2 (g) 276 238 156
    Deformation at hardness (mm) 1.58 1.67 1.68
    Stringiness Length (mm) 64.2 69.26 22.53
    Adhesiveness (mJ) 1.1 0.6 0.5
    Cohesiveness 0 0.03 0.1
    Gumminess (g) −1 58 149
    Chewiness (mJ) 0 1.6 5
    Springiness 0.92 2.75 3.45
  • Tables 26-28 show the results accelerated stability study of the tablets formed according to Examples 12-14, respectively. The tablets were packaged in a high-density polyethylene (HDPE) container and stored at a temperature of 40° C.±2° C. and a relative humidity (RH) of 75%±5%.
  • TABLE 26
    Stability Parameters Initial 1-Month 3-Months
    Loss On Drying 5.66 6.64 6.71
    (LOD) at 105° C.
    Assay (%) 96.6 97.4 95.9
    Dissolution (%) 99 98 93
    Related 0.078 ND 0.14
    Substances (%) 0.145 0.14 0.21
  • TABLE 27
    Stability Parameters Initial 1-Month 3-Months
    Loss On Drying 7.12 7.01 7.14
    (LOD) at 105° C.
    Assay (%) 98.8 100.3 99
    Dissolution (%) 94 94 88
    Related 0.082 ND 0.19
    Substances (%) 0.198 0.17 0.25
  • TABLE 28
    Stability Parameters Initial 1-Month 3-Months
    Loss On Drying 7.2 6.89 6.68
    (LOD) at 105° C.
    Assay (%) 94.2 99.6 97.6
    Dissolution (%) 92 76 83
    Related 0.074 ND 0.15
    Substances (%) 0.173 0.14 0.22
  • Ingredients corresponding to Example 15 are tabulated in Table 29. The active ingredient in the formulation of Example 15 is enrofloxacin. The active strength of enrofloxcin used in the Example 15 formulation was 22.7 mg or 68 mg or 136 mg.
  • TABLE 29
    Ingredient % wt./wt
    Granulation Aid Ingredients
    Mineral Oil 7
    Glycerin 18
    Polyethylene Glycol (PEG-600) 1.5
    Povidone (K-30) 0.15
    Brown Iron Oxide 0.01
    Intra-granular Ingredients
    Enrofloxacin 4.53
    Carnauba wax 4
    Lactose 8.5
    Silicified Microcrystalline Cellulose 15.21
    Calcium Sulfate Dihydrate 2
    Beef Flavor 15
    Croscarmellose Sodium 4.5
    Extra-granular Ingredients
    Pregelatinized Starch 3
    Silicified Microcrystalline Cellulose 2.5
    Beef Flavor 3
    Croscarmellose Sodium 6.9
    Lactose 2
    Flow Aid Ingredients
    Sodium Stearyl Fumarate 2
    Sodium Lauryl Sulphate 0.2
    Total 100
    • Procedure—Example 15
      • Step 1: Intra-granular ingredients (enrofloxacin, silicified microcrystalline cellulose, carnauba wax, pregelatinized starch, beef flavor, croscarmellose sodium, and calcium sulphate dihydrate) were passed through simultaneously through #40 mesh screen and once again passed through #40 mesh screen followed by mixing.
      • Step 2: Extra-granular ingredients (pregelatinized starch, beef flavor, silicified microcrystalline cellulose, lactose and croscarmellose sodium) were passed through simultaneously through #40 mesh screen using mechanical sifter and resifted once through #40 mesh screen and approximately divided into two parts (75% and 25%).
      • Step 3: Sodium stearyl fumarate and sodium lauryl sulphate passed through simultaneously through #40 mesh screen and again passed through #40 mesh screen.
      • Step 4: Glycerin and polyethylene glycol were mixed in a vessel under stirring to form dispersion.
      • Step 5: Povidone was added to dispersion from Step 4 under continuous stirring to obtain a clear, lump free dispersion.
      • Step 6: Brown iron oxide added to dispersion from Step 5 under continuous stirring to obtain a lump free dispersion.
      • Step 7: Mineral oil was added to materials from Step 1.
      • Step 8: Dispersion from Step 6 was added to contents from Step 7 to form a wet mass.
      • Step 9: Wet mass from Step 8 was kneaded for up to one (1) minute.
      • Step 10: Wet mass from Step 9 and 75% extra-granular materials from Step 2 were passed simultaneously through cone-mill using six millimeter (6 mm) screen at slow speed and knife forward to form granules.
      • Step 11: Granules from Step 10 were further sifted by passing through #8 mesh screen.
      • Step 12: Granules from Step 11 and remaining 25% extra-granular materials from Step 2 were blended together for 3 minutes.
      • Step 13: Sodium Stearyl Fumarate and Sodium Lauryl sulphate from Step 3 were added to final granules from Step 12 and mixed together for 2 minutes.
      • Step 14: Compression was done using following tooling on a rotary tablet press. With respect to the Example 15 formulation having a enrofloxacin strength of 22.7 mg, a 10.5 mm×10.5 mm rounded square shape punch was used to compress a tablet having a 500 mg fill weight. With respect to the Example 15 formulation having a enrofloxacin strength of 68 mg, a 15.3 mm×15.3 mm rounded square shape punch was used to compress a tablet having a 1500 mg fill weight. With respect to the Example 15 formulation having a enrofloxacin strength of 136 mg, an 18.0 mm×18.0 mm rounded square shape punch was used to compress a tablet having a 3000 mg fill weight.
    Table 23: Tablet Characterization—Example 15
  • TABLE 30
    Example 15 Example 15 Example 15
    Parameters 22.7 mg 68 mg 136 mg
    Weight (mg) 500 1500 3000
    Shape Rounded Rounded Rounded
    Square Square Square
    Color Light brown Light brown Light brown
    to brown to brown to brown
    Area-Top (mm) 10.5 × 10.5 15.3 × 15.3 18.0 × 18.0
    Width × Length
    Area-Bottom (mm) 10.5 × 10.5 15.3 × 15.3 18.0 × 18.0
    Width × Length
    Thickness (mm) 4.5 6.8 9
    Disintegration 5 min 7 min 9 min
    Time (min)
    Hardness (N) 0 0 0
    Friability (%) 0 0 0
  • The results of a texture analysis of the tablets formed according to Example 15 are tabulated in Table 31. The texture analysis was performed using a CT3 Texture Analyzer (Brookfield Engineering) using a TA18 Probe and twenty-five-thousand gram (25,000 g) load cell and five gram (5 g) trigger load, over four millimeters (4 mm) using two millimeter per second (2 mm/s) test speed and using a data rate of twenty (20) points/second.
  • TABLE 31
    Example 15 Example 15 Example 15
    Parameters 22.7 mg 68.0 mg 136 mg
    Hardness Cycle 1 (g) 3348 1994 3142
    Hardness Cycle 2 (g) 1186 232 6
    Deformation at 3.97 0.96 1.27
    hardness (mm)
    Stringiness Length 0 50.37 0
    (mm)
    Adhesiveness (mJ) 0 −0.1 0
    Cohesiveness 0.03 0.09 0
    Gumminess (g) 116 185 0
    Chewiness (mJ) 1.1 122.8 0
    Springiness 0.25 67.84 1
  • The results of a comparative dissolution study involving the tablets formed according to Example 15 are tabulated in Tables 32-34. The dissolution profiles of Example 15 were compared to marketed products having similar active strengths. A paddle apparatus rotating at 100 rpm was used. Nine-hundred milliliters (900 ml) of pH 4.0 citrate buffer was used as the dissolution medium.
  • TABLE 32
    Marketed
    Time product Example 15
    point 22.7 mg 22.7 mg
    0 0 0
    5 71 64
    10 99 90
    15 99 99
    30 99 99
    45 99 99
  • TABLE 33
    Marketed
    Time product Example 15
    point 68 mg 68 mg
    0 0 0
    5 48 59
    10 82 82
    15 97 95
    30 97 98
    45 97 98
  • TABLE 34
    Marketed
    Time product Example 15
    point 100 mg 100 mg
    0 0 0
    5 45 45
    10 70 68
    15 89 81
    30 98 98
    45 98 99
  • Ingredients corresponding to Examples 16-18 are tabulated in Table 35, with the amount of each ingredient given in respective percent by weight (w/w %). In each of the Examples 16-18, the active ingredient is enrofloxacin. In Example 16, the active strength of enrofloxacin is about 22.7 mg. In Example 17, the active strength of enrofloxacin is about 68 mg. In Example 18, the active strength of enrofloxacin is about 136 mg.
  • TABLE 35
    Example Example Example
    Ingredient 16 17 18
    Granulation Aid Ingredients
    Mineral Oil 7 7 7
    Glycerin 16 14 16
    Polyethylene Glycol (PEG-600) 4 6 4
    Povidone (K-30) 0.25 0.25 0.25
    Brown Iron Oxide 0.01 0.01 0.01
    Intra-granular Ingredients
    Enrofloxacin 4.53 4.53 4.53
    Carnauba wax 4 6 4
    Lactose 15.21 13.71 15.21
    Silicified Microcrystalline Cellulose 8.5 8 8.5
    Calcium Sulfate Dihydrate 2 2 2
    Beef Flavor 15 15 15
    Croscarmellose Sodium 4.5 4.5 4.5
    Extra-granular Ingredients
    Pregelatinized Starch 3 3 3
    Silicified Microcrystalline Cellulose 6.3 6.3 6.3
    Beef Flavor 3 3 3
    Croscarmellose Sodium 4.5 4.5 4.5
    Flow Aid Ingredients
    Sodium Stearyl Fumarate 2 2 2
    Sodium Lauryl Sulphate 0.2 0.2 0.2
    Total 100 100 100
    • Procedure—Examples 16-18
      • Step 1: All intra-granular materials (enrofloxacin, carnauba wax, lactose monohydrate, silicified microcrystalline cellulose, calcium sulphate dihydrate, beef flavor and croscarmellose sodium) were passed through #40 mesh screen and mixed further.
      • Step 2: All extra-granular materials (pregelatinized starch, silicified microcrystalline cellulose, croscarmellose sodium and beef flavor) were passed through #40 mesh screen and approximately divided into two equal parts.
      • Step 3: Sodium stearyl fumarate and sodium lauryl sulphate were passed through #40 mesh screen and mixed further.
      • Step 4: Povidone was added to glycerin and polyethylene glycol under continuous stirring to get clear dispersion.
      • Step 5: Brown iron oxide was further added to dispersion from Step 4 under continuous stirring to get lump free dispersion.
      • Step 6: Final contents from Step 5 were added to the contents from Step 1 and mixed thoroughly followed by addition of mineral oil and mixing thoroughly to form wet mass.
      • Step 7: Wet mass from Step 6 was passed through multi-mill using six millimeter (6 mm) screen to form granules.
      • Step 8: Approximately half quantity of extra-granular contents from Step 2 and granules of Step 7 were passed though simultaneously #8 mesh screen.
      • Step 9: Remaining half quantity of extra-granular contents from Step 2 and granules from of Step 8 were mixed together for one (1) minute.
      • Step 10: Materials from Step 3 were added to granule from Step 9 and mixed together for one (1) minute.
      • Step 11: Compression was done using tooling on a rotary tablet press. With respect to Example 16, a 10.5 mm×10.5 mm rounded square shape punch was used to compress a tablet having a 500 mg fill weight. With respect to Example 17, a 15.3 mm×15.3 mm rounded square shape punch was used to compress a tablet having a 1500 mg fill weight. With respect to Example 18, an 18.0 mm×18.0 mm rounded square shape punch was used to compress a tablet having a 3000 mg fill weight.
    Table 36: Tablet Characterization—Examples 16-18
  • TABLE 36
    Parameters Example 16 Example 17 Example 18
    Weight (mg) 500 1500 3000
    Shape Rounded Rounded Rounded
    Square Square Square
    Color Light brown Light brown Light brown
    to brown to brown to brown
    Width × Length 10.5 × 10.5 14.5 × 14.5 18.0 × 18.0
    Top (mm)
    Width × Length 10.5 × 10.5 15.3 × 15.3 18.0 × 18.0
    Bottom (mm)
    Thickness (mm) 4.5 6.6 8.9
    Disintegration 5 min 15 min 10 min
    Time (min)
    Hardness (N) 0 0 0
    Friability (%) 0 0 0
  • The results of a texture analysis of the tablets formed according to Examples 16-18 are tabulated in Table 37. The texture analysis was performed using a CT3 Texture Analyzer (Brookfield Engineering) using a TA18 Probe and twenty-five-thousand gram (25,000 g) load cell and five gram (5 g) trigger load, over four millimeters (4 mm) using two millimeter per second (2 mm/s) test speed and using a data rate of twenty (20) points/second.
  • TABLE 37
    Example Example Example
    Parameters 16 17 18
    Hardness Cycle 1 (g) 2966 1068 1496
    Hardness Cycle 2 (g) 1060 186 146
    Deformation at 3.97 1.2 1.79
    hardness (mm)
    Stringiness Length 66.02 70.16 48.86
    (mm)
    Adhesiveness (mJ) 1.1 0.5 −0.1
    Cohesiveness 0.01 −0.1 0.06
    Gumminess (g) 16 −8 91
    Chewiness (mJ) 0.1 −0.1 53.3
    Springiness 0.76 0.89 59.89
  • Tables 38-40 show the results accelerated stability study of the tablets formed according to Examples 16-18, respectively. The tablets were packaged in a high-density polyethylene (HDPE) container and stored at a temperature of 40° C.±2° C. and a relative humidity (RH) of 75%±5%.
  • TABLE 38
    Stability Parameters Initial 1-Month 3-Months
    Loss On Drying 7.6 10.82 10.2
    (LOD) at 105° C.
    Assay (%) 101.6 101.8 98.4
    Dissolution (%) 105.2 103.4 106
    Related 0.147 0.077 0.13
    Substances (%) 0.22 0.286 0.26
  • TABLE 39
    Stability Parameters Initial 1-Month 3-Months
    Loss On Drying 8.1 9.42 9
    (LOD) at 105° C.
    Assay (%) 98.9 100 98.5
    Dissolution (%) 103.4 99.5 102
    Related 0.15 0.073 0.18
    Substances (%) 0.22 0.272 0.31
  • TABLE 40
    Stability Parameters Initial 1-Month 3-Months
    Loss On Drying 7.6 12.01 11.03
    (LOD) at 105° C.
    Assay (%) 100.1 100 99
    Dissolution (%) 100.8 98 100
    Related 0.135 0.074 0.2
    Substances (%) 0.207 0.272 0.33
  • Ingredients corresponding to Examples 19-23 are tabulated in Table 41, with the amount of each ingredient given in respective percent by weight (w/w %). In each of the Examples 19-23, the active ingredient is deracoxib. In Example 19, the active strength of deracoxib is about 12 mg. In Example 20, the active strength of deracoxib is about 25 mg. In Example 21, the active strength of deracoxib is about 50 mg. In Example 22, the active strength of deracoxib is about 75 mg. In Example 23, the active strength of deracoxib is about 100 mg.
  • TABLE 41
    Exam- Exam- Exam- Exam- Exam-
    ple ple ple ple ple
    Ingredient 19 20 21 22 23
    Granulation Aid Ingredients
    Mineral Oil
    8 8 8 8 8
    Sorbitol 15.5 15.5 15.5 15.5 15.5
    Polyethylene Glycol 3.5 3.5 3.5 3.5 3.5
    (PEG-600)
    Povidone (K-30) 0.2 0.2 0.2 0.2 0.2
    Brown Iron Oxide 0.01 0.01 0.01 0.01 0.01
    Intra-granular Ingredients
    Deracoxib 3.33 3.33 3.33 3.33 3.33
    Carnauba Wax 4 4 4 4 4
    Lactose Monohydrate 17.1 17.1 17.1 17.1 17.1
    Silicified Microcrystalline 6.4 6.4 6.4 6.4 6.4
    Cellulose
    Pregelatinized Starch
    1 1 1 1 1
    Calcium Sulfate Dihydrate 2 2 2 2 2
    Beef Flavor 15 15 15 15 15
    Croscarmellose Sodium 5 5 5 5 5
    Extra-granular Ingredients
    Lactose Monohydrate
    5 2 5 7 5
    Silicified Microcrystalline 5.86 5.86 5.86 5.86 5.86
    Cellulose
    Beef Flavor 3 3 3 3 3
    Croscarmellose Sodium 3 6 3 1 3
    Flow Aid Ingredients
    Sodium Stearyl Fumarate 2 2 2 2 2
    Sodium Lauryl Sulphate 0.1 0.1 0.1 0.1 0.1
    Total 100 100 100 100 100
    • Procedure—Examples 19-23
      • Step 1: All intra-granular materials (deracoxib, carnauba wax, lactose monohydrate, silicified microcrystalline cellulose, pregelatinized starch, calcium sulphate dihydrate, beef flavor and croscarmellose sodium) were passed simultaneously through #40 mesh screen and mixed further.
      • Step 2: All extra-granular materials (lactose monohydrate, silicified microcrystalline cellulose, croscarmellose sodium and beef flavor) were passed simultaneously through #40 mesh screen and mixed further and divided into approximately two parts (75% and 25%).
      • Step 3: Sodium stearyl fumarate and sodium lauryl sulphate were passed simultaneously through #40 mesh and mixed further.
      • Step 4: Povidone was added into sorbitol and polyethylene glycol under continuous stirring to get clear dispersion.
      • Step 5: Brown iron oxide was added to dispersion from Step 4 under continuous stirring to get lump free dispersion.
      • Step 6: All granulation aid components except mineral oil were added to the contents from step 1 and mixed thoroughly until uniformly mixed, followed by quick addition of mineral oil followed by mixing thoroughly to form wet mass.
      • Step 7: Wet mass from Step 6 was passed through multi-mill using six millimeter (6 mm) screen to form granules.
      • Step 8: Approximately 75% quantity of extra-granular materials from Step 2 and granules of Step 7 were passed through #8 mesh screen using vibro-sifter.
      • Step 9: Remaining quantity of extra-granular materials (25%) from Step 2 and sifted granules of Step 8 were mixed together for two (2) minutes.
      • Step 10: Materials from Step 3 were added to granules from Step 10 and mixed together for two (2) minutes.
      • Step 11: Final granules from Step 10 were compressed using following punches on rotary tablet press. With respect to Example 19, an 8.0 mm×8.0 mm rounded square shape punch was used to compress a tablet having a 360 mg fill weight. With respect to Example 20, a 12.3 mm×12.3 mm rounded square shape punch was used to compress a tablet having a 750 mg fill weight. With respect to Example 21, a 15.3 mm×15.3 mm rounded square shape punch was used to compress a tablet having a 1500 mg fill weight. With respect to Example 22, a 17.0 mm×17.0 mm rounded square shape punch was used to compress a tablet having a 2250 mg fill weight. With respect to Example 23, an 18.0 mm×18.0 mm rounded square shape punch was used to compress a tablet having a 3000 mg fill weight.
    Table 42: Tablet Characterization—Examples 19-23
  • TABLE 42
    Example Example Example Example Example
    Parameters 19 20 21 22 23
    Weight (mg) 360 750 1500 2250 3000
    Shape Rounded Rounded Rounded Rounded Rounded
    Square Square Square Square Square
    Color Light Light Light Light Light
    brown brown brown brown brown
    to brown to brown to brown to brown to brown
    Width × 8.0 X 8.0 12.3 × 12.3 15.3 × 15.3 17.0 × 17.0 18.0 × 18.0
    Length
    Top (mm)
    Width x 8.0 X 8.0 12.3 × 12.3 15.3 × 15.3 17.0 × 17.0 18.0 × 18.0
    Length
    Bottom
    (mm)
    Thickness 5.3 4.9 6.2 7.5 8.9
    (mm)
    Dis- 7 min 4 min 6 min 10 min 8 min
    integration
    Time (min)
    Hardness 0 0 0 0 0
    (N)
    Friability 0 0 0 0 0
    (%)
  • The results of a texture analysis of the tablets formed according to Examples 19-23 are tabulated in Table 43. The texture analysis was performed using a CT3 Texture Analyzer (Brookfield Engineering) using a TA18 Probe and twenty-five-thousand gram (25,000 g) load cell and five gram (5 g) trigger load, over four millimeters (4 mm) using two millimeter per second (2 mm/s) test speed and using a data rate of twenty (20) points/second.
  • TABLE 43
    Exam- Exam- Exam- Exam- Exam-
    ple ple ple ple ple
    Parameters 19 20 21 22 23
    Hardness Cycle 1 (g) 1890 5904 1764 1768 2866
    Hardness Cycle 2 (g) 744 1886 242 162 180
    Deformation at 3.99 3.94 1.59 1.68 1.78
    hardness (mm)
    Stringiness Length (mm) 62.17 0 7.88 0 0
    Adhesiveness (mJ) 0 1.5 0.1 0.6 −0.1
    Cohesiveness 0.04 0.01 0.03 0.01 0.03
    Gumminess (g) 83 62 45 24 81
    Chewiness (mJ) 0.8 0.4 0.6 0.7 42.2
    Springiness 0.99 0.68 1.28 3.09 52.88
  • The results of a comparative dissolution study involving the tablets formed according to Examples 19-23 are tabulated in Tables 44-48, respectfully. The dissolution profiles of Examples 19-23 were compared to a marketed products having similar active strengths. A paddle apparatus rotating at 75 rpm. Nine-hundred milliliters (900 ml) of pH 12.4 phosphate buffer with 1% SLS was used as the dissolution medium.
  • TABLE 44
    Marketed Product
    Time point
    12 mg Example 19
    0 0 0
    5 57 76
    10 88 100
    15 96 103
    30 97 104
    45 96 104
  • TABLE 45
    Marketed Product
    Time point
    25 mg Example 20
    0 0 0
    5 46 46
    10 77 74
    15 92 90
    30 97 98
    45 97 99
  • TABLE 46
    Time Example
    point 21
    0 0
    5 46
    10 69
    15 87
    30 98
    45 98
  • TABLE 47
    Marketed Product
    Time point 75 mg Example 22
    0 0 0
    5 34 37
    10 53 61
    15 66 77
    30 75 98
    45 87 100
  • TABLE 48
    Marketed Product
    Time point
    100 mg Example 23
    0 0 0
    5 37 26
    10 56 50
    15 71 68
    30 82 92
    45 95 96
  • Tables 49-53 show the results accelerated stability study of the tablets formed according to Examples 19-23, respectively. The tablets were packaged in a high-density polyethylene (HDPE) container and stored at a temperature of 40° C.±2° C. and a relative humidity (RH) of 75%±5%.
  • TABLE 49
    Stability Parameters Initial 1-Month 3-Months
    Loss On Drying 12.97 9.24 8.95
    (LOD) at 105° C.
    Assay (%) 102.8 100.9 99.6
    Dissolution (%) 104 100 102
    Related ND ND ND
    Substances (%) ND ND ND
  • TABLE 50
    Stability Parameters Initial 1-Month 3-Months
    Loss On Drying 9.52 8.2 8.5
    (LOD) at 105° C.
    Assay (%) 103.4 100.9 98.7
    Dissolution (%) 99 100 104
    Related ND ND ND
    Substances (%) ND ND ND
  • TABLE 51
    Stability Parameters Initial 1-Month 3-Months
    Loss On Drying 12.97 10.14 7.26
    (LOD) at 105° C.
    Assay (%) 99.2 100.5 96.7
    Dissolution (%) 97 96 92
    Related ND ND ND
    Substances (%) ND ND ND
  • TABLE 52
    Stability
    Parameters Initial 1-Month 3-Months
    Loss On Drying 8.24 10.11 6.89
    (LOD) at 105° C.
    Assay (%) 98.4 101.5 99.9
    Dissolution (%) 100 93 99
    Related ND ND ND
    Substances (%) ND ND ND
  • TABLE 53
    Stability
    Parameters Initial 1-Month 3-Months
    Loss On Drying 12.97 10.02 8.23
    (LOD) at 105° C.
    Assay (%) 103.3 100.6 100.9
    Dissolution (%) 97 89 92
    Related ND ND ND
    Substances (%) ND ND ND
  • Ingredients corresponding to Examples 24 and 25 are tabulated in Table 54, with the amount of each ingredient given in respective percent by weight (% w/w). In each of the Examples 24 and 25, the active ingredient is marbofloxacin. In Example 24 formulations, the active strength of marbofloxacin is about 25 mg or about 50 mg or about 100 mg. In Example 25 formulations, the active strength of marbofloxacin is about 200 mg.
  • TABLE 54
    Example Example
    Ingredients 24 25
    Granulation Aid
    Mineral Oil 7 7
    Glycerin 16 17
    Polyethylene glycol (PEG 4.5 4
    600)
    Povidone (K-30) 1.5 1
    Brown Iron Oxide 0.01 0.01
    Intra-granular Ingredients
    Marbofloxacin 6.67 6.67
    Carnauba wax 3 4
    Silicified Microcrystalline 22.72 22.72
    Cellulose
    Pregelatinized starch 1500 3 3
    Polyethylene glycol (PEG 5 2.5
    4000)
    Calcium Sulphate dihydrate 2 2
    Beef Flavor 15 15
    Extra-granular Ingredients
    Pregelatinized starch 1500 2 3.5
    Silicified Microcrystalline 7 7
    Cellulose
    Beef Flavor 3 3
    Lubrication Aid
    Magnesium Stearate 1.5 1.5
    Sodium Lauryl Sulphate 0.1 0.1
    Total 100 100
    • Procedure—Examples 24 and 25
      • Step 1: Intra-granular materials (marbofloxacin, carnauba wax, silicified mcc, pregelatinized starch, polyethylene glycol, calcium sulphate dehydrate and beef flavor) were passed simultaneously through #40 mesh screen and mixed together.
      • Step 2: Intra-granular materials (pregelatinized starch, silicified mcc and beef flavor) were passed simultaneously through #40 mesh screen, mixed together and divided into approximately two parts (75% and 25%).
      • Step 3: Sodium stearyl fumarate and sodium lauryl sulphate were passed through #40 mesh and mixed together.
      • Step 4: Povidone was added into glycerin and polyethylene glycol under continuous stirring to get clear dispersion.
      • Step 5: Brown iron oxide was added to dispersion from Step 4 under continuous stirring to get lump free dispersion.
      • Step 6: All granulation aid components except mineral oil were added to contents from Step 1 and mixed thoroughly, followed by addition of mineral oil and mixing to form and granulated wet mass.
      • Step 7: Wet mass from Step 6 was further passed through multi-mill using 6 mm screen.
      • Step 8: Approximately 75% quantity of extra-granular materials from Step 2 and milled granules from Step 7 were passed simultaneously through #8 mesh.
      • Step 9: Remaining quantity (25%) of extra-granular materials and granules from Step 8 were mixed together for 2 minute.
      • Step 10: Materials from Step 3 were added to granules from Step 9 and mixed together for 2 minute.
      • Step 11: Final granules were compressed on rotary tablet press using tooling. With respect to Example 24 having a 25 mg active strength, an 8.0 mm×8.0 mm rounded square shape punch was used to compress a tablet having a 375 mg fill weight. With respect to Example 24 having a 50 mg active strength, a 10.5 mm×10.5 mm rounded square shape punch was used to compress a tablet having a 750 mg fill weight. With respect to Example 24 having a 100 mg active strength, a 15.3 mm×15.3 mm rounded square shape punch was used to compress a tablet having a 1500 mg fill weight. With respect to Example 25 having a 200 mg active strength, an 18.0 mm×18.0 mm rounded square shape punch was used to compress a tablet having a 3000 mg fill weight.
    Table 55: Tablet Characterization—Examples 27 and 28
  • TABLE 55
    Example Example Example Example
    Parameters 24 24 24 25
    Active Strength 25 mg 50 mg 100 mg 200 mg
    Weight (mg) 375 750 1500 3000
    Shape Rounded Rounded Rounded Deep
    Square Square Square Rounded
    Square
    Color Light brown Light brown Light brown Light brown
    to brown to brown to brown to brown
    Width × Length 8.0 × 8.0 10.5 × 10.5 15.3 × 15.3 18.0 × 18.0
    Top (mm)
    Width × Length 8.0 × 8.0 10.5 × 10.5 15.3 × 15.3 18.0 × 18.0
    Bottom (mm)
    Thickness 5.6 6.6 6.3 9.2
    (mm)
    Disintegration 17 21 21 26
    Time (min.)
    Hardness (N) 0 0 0 0
    Friability (%) 0 0 0 0
  • The results of a texture analysis of the tablets formed according to Examples 24 and 25 are tabulated in Table 56. The texture analysis was performed using a CT3 Texture Analyzer (Brookfield Engineering) using a TA18 Probe and twenty-five-thousand gram (25,000 g) load cell and five gram (5 g) trigger load, over four millimeters (4 mm) using two millimeter per second (2 mm/s) test speed and using a data rate of twenty (20) points/second.
  • TABLE 56
    Example Example Example Example
    Parameters 24 24 24 25
    Strength 25 mg 50 mg 100 mg 200 mg
    Hardness Cycle 1 (g) 916 1642 2062 2802
    Hardness Cycle 2 (g) 3.8 254 146 274
    Deformation at 0.99 1.39 2.09 1.76
    hardness (mm)
    Stringiness Length 51.97 39.37 47.02 0
    (mm)
    Adhesiveness (mJ) 0.1 0 0.2 1.7
    Cohesiveness 0.14 0.14 0.1 0.02
    Gumminess (g) 125 227 212 66
    Chewiness (mJ) 4 9.3 17.3 2.3
    Springiness 3.24 4.19 8.32 3.47
  • The results of a comparative dissolution study involving the tablets formed according to Example 24 are tabulated in Tables 57-59. The results of a comparative dissolution study involving the tablets formed according to Example 25 are tabulated in Table 60. The dissolution profiles of Examples 24 and 25 were compared to marketed products having similar active strengths using a basket apparatus rotating at 100 rpm. One-thousand milliliters (1000 ml) of 0.1 N HCl solution was used as the dissolution medium.
  • TABLE 57
    Marketed
    Time Product Example 24
    point 25 mg 25 mg
    0 0 0
    5 4 12
    15 42 53
    30 87 95
    45 101 101
    60 101 98
    90 102 101
    120 102 101
  • TABLE 58
    Marketed
    Time Product Example 24
    point 50 mg 50 mg
    0 0 0
    5 2 10
    15 33 40
    30 74 73
    45 98 94
    60 99 97
    90 100 97
    120 100 98
  • TABLE 59
    Marketed Example
    Time Product 24
    point 100 mg 100 mg
    0 0 0
    5 1 7
    15 16 34
    30 48 63
    45 75 84
    60 93 98
    90 99 99
    120 99 99
  • TABLE 60
    Marketed Example
    Time Product
    25
    point 200 mg 200 mg
    0 0 0
    5 1 10
    15 17 40
    30 46 72
    45 68 91
    60 85 99
    90 99 100
    120 99 100
  • Tables 61-63 show the results accelerated stability study of the tablets formed according to Example 24. Table 64 shows the results accelerated stability study of the tablets formed according to Example 25. The tablets were packaged in a high-density polyethylene (HDPE) container stored at a temperature of 40° C.±2° C. and a relative humidity (RH) of 75%±5%.
  • TABLE 61
    Example 24 (25 mg)
    Stability 1- 3-
    Parameters Initial Month Months
    Loss On Drying 4.67 5.39 9.64
    (LOD) at 105° C.
    Assay (%) 96.3 97.9 0.95
    Dissolution (%) 98 100 102
    Related 0.69 0.93 0.81
    Substances (%)
  • TABLE 62
    Example 24 (50 mg)
    Stability 1- 3-
    Parameters Initial Month Months
    Loss On Drying 4.67 5.26 9.35
    (LOD) at 105° C.
    Assay (%) 97.3 99.7 96.1
    Dissolution (%) 97 99 99
    Related 0.49 0.76 0.82
    Substances (%)
  • TABLE 63
    Example 24 (100 mg)
    Stability 1- 3-
    Parameters Initial Month Months
    Loss On Drying 4.56 6.01 9.51
    (LOD) at 105° C.
    Assay (%) 101.6 102.7 98.1
    Dissolution (%) 98 99 98
    Related 0.55 0.8 0.58
    Substances (%)
  • TABLE 64
    Example 24 (200 mg)
    Loss On Drying 5.45 5.61 8.09
    (LOD) at 105° C.
    Assay (%) 102.7 99.1 101.7
    Dissolution (%) 99 95 98
    Related 0.47 0.37 0.32
    Substances (%)
  • Ingredients corresponding to Examples 26-28 are tabulated in Table 65, with the amount of each ingredient given in respective percent by weight (% w/w). In each of the Examples 26-28, the active ingredient is pimobendan. In each of the Examples 26-28, the active strength of pimobendan is about 10 mg.
  • TABLE 65
    Example Example Example
    Ingredients 26 27 28
    Granulation Aid Ingredients
    Soybean Oil
    8 8 —
    Mineral Oil — — 4.71
    BHA (Butylated Hydroxyanisole ) 0.02 0.02 —
    BHT (Butylated Hydroxytoluene ) 0.08 0.08 —
    Polyethylene glycol (PEG 600) — — 2.83
    Polysorbate 80 — — 2.83
    Tartaric Acid — — 4.72
    Glycerin — — 17.32
    Pimobendan 0.33 0.33 0.33
    Cremophor 5 3 —
    Cirtic Acid — 8 —
    Sorbitol 16 11 —
    Povidone (K-30) 0.2 0.2 0.19
    Brown Iron Oxide 0.01 0.01 0.01
    Intra-granular Ingredients
    Carnauba wax
    5 5 4.72
    Sodium Lauryl Sulphate 1 — —
    Mannitol 12.76 — —
    Lactose Monohydrate 6 3.5
    Pregelatinized Starch — — 2
    Soluplus 5 5 4.72
    Silicified Microcrystalline Cellulose — 14.76 13.72
    Calcium Sulfate Dihydrate 2 2 2
    Beef Flavor 15 15 15
    Calcium Carboxymethyl 5.5 — 5
    cellulose (ECG 505)
    Croscarmellose Sodium 6 4.5 —
    Extra-granular Ingredients
    Calcium Carboxymethyl cellulose 5.5 1.6 3
    (ECG 505)
    Silicified Microcrystalline Cellulose 2 2.5 2
    Beef Flavor 3 3 3
    Croscarmellose Sodium 4.5 6 4.7
    Lactose Monohydrate — — 1.7
    (Supertab 14 SD)
    Lactose Monohydrate 2 2 —
    (Granulac 200)
    Flow Aid Ingredients
    Magnesium Stearate
    1 — —
    Sodium Lauryl Sulphate 0.1 — —
    Sodium Stearyl Fumarate — 2 2
    Total 100 100 100
    • Procedure—Example 26
      • Step 1: pimobendan was added in cremophor under continuous stirring to achieve homogenous dispersion
      • Step 2: BHA and BHT were added to soybean oil, mixed thoroughly and added to contents from Step 1.
      • Step 3: In separate vessel povidone was added to sorbitol under continuous stirring to form clear dispersion followed by addition of brown iron oxide under continuous stirring to form lump free dispersion.
      • Step 4: Intra-granular materials (sodium lauryl sulphate, carnauba wax, mannitol, soluplus, calcium carboxymethyl cellulose, calcium sulphate dihydrate, beef flavor and croscarmellose sodium) were passed simumulatinsly through #40 mesh screen and again were passed through #40 mesh screen and mixed together for ten minutes.
      • Step 5: Extra-granular materials (calcium carboxymethyl cellulose, silicified microcrystalline cellulose, lactose monohydrate, beef flavor and croscarmellose sodium) were passed simultaneously through #40 mesh screen and once gain were passed through #40 mesh screen and mixed together and further divided to two equal parts.
      • Step 6: Magnesium stearate and sodium lauryl sulphate were passed through #40 mesh screen.
      • Step 7: Granulation aid components were added to materials from Step 4 and mixed thoroughly followed by kneading for about two (2) minutes.
      • Step 8: Wet mass from Step 7 was passed through cone mill using six millimeter (6 mm) screen to form granules.
      • Step 9: Approximately 50% quantity of extra-granular materials from Step 5 and milled granules of Step 8 were passed through #8 mesh screen.
      • Step 10: Remaining quantity of extra-granular materials (50%) of
      • Step 5 were mixed with granules from Step 9 and mixed together for two (2) minutes.
      • Step 11: Materials from Step 6 were further added to granules from Step 12 and mixed together for two (2) minutes.
      • Step 12: Using final granules from Step 11 compression was performed using rotary tablet press using 18.0 mm×18.0 mm rounded square shape punch.
    Procedure—Example 27
      • Step 1: Pimobendan was added in cremophor under continuous stirring to achieve homogenous dispersion
      • Step 2: BHA and BHT were added to soybean oil, mixed thoroughly and added to contents from Step 1.
      • Step 3: In separate vessel citric acid was added to sorbitol under continuous stirring to form clear dispersion.
      • Step 4: Povidone was added to dispersion from Step 3 under continuous stirring to form clear dispersion.
      • Step 5: Brown iron oxide was added to dispersion from Step 4 under continuous stirring to form uniform dispersion.
      • Step 6: Intra-granular materials (carnauba wax, lactose monohydrate, soluplus, silicified microcrystalline cellulose, calcium sulphate dihydrate, beef flavor and croscarmellose sodium) were passed simultaneously through #40 mesh screen followed by passing again through #40 mesh and mixing together for ten minutes.
      • Step 7: Extra-granular material (calcium carboxymethyl cellulose, silicified microcrystalline cellulose, lactose monohydrate, beef flavor and croscarmellose sodium) were passed through #40 mesh screen and followed by passing again through #40 mesh and mixing together and were divided further to two equal parts.
      • Step 8: Sodium stearyl fumarate was passed through #40 mesh screen.
      • Step 9: Granulation aid components were added to the materials from Step 6 and mixed thoroughly followed by kneading for about two (2) minutes to form wet mass.
      • Step 10: Wet mass from Step 9 was passed through cone mill using six millimeter (6 mm) screen to form granules.
      • Step 11: Approximately 50% quantity of extra-granular materials from Step 7 and milled granules of Step 10 were passed simultaneously through #8 mesh screen.
      • Step 12: Remaining quantity of extra-granular materials (50%) from Step 7 were mixed with granules from Step 11 and mixed together for two (2) minutes.
      • Step 13: Material from Step 8 was added to granules from Step 12 and mixed together for two (2) minutes.
      • Step 14: Granules from Step 13 were used for compression using rotary tablet press using 18.0 mm×18.0 mm rounded square shape punch.
    Procedure—Example 28
      • Step 1: Intra-granular materials (carnauba wax, lactose monohydrate, soluplus, silicified microcrystalline cellulose, calcium sulphate dihydrate, beef flavor, calcium carboxymethyl cellulose and croscarmellose sodium) were passed simultaneously through #40 mesh screens and passed again through #40 mesh screen followed by mixing together for ten minutes.
      • Step 2: Extra-granular materials (calcium carboxymethyl cellulose, silicified microcrystalline cellulose, lactose monohydrate, beef flavor and croscarmellose sodium) were passed through #40 mesh screen simultaneously and passed again through #40 mesh screen followed by mixing together and further approximately dividing to two parts (75% and 25%).
      • Step 3: Sodium stearyl fumarate was sifted through #40 mesh screen.
      • Step 4: Glycerin and polyethylene glycol kept in a vessel under stirring.
      • Step 5: Tartaric acid was added to materials from Step 4 under continuous stirring to get a lump free dispersion.
      • Step 6: Povidone was added into dispersion from Step 5 under continuous stirring to obtain a clear, lump free dispersion.
      • Step 7: Brown iron oxide was added into contents from Step 6 under continuous stirring to obtain a lump free dispersion.
      • Step 8: Pimobendan was added in polysorbate 80 under continuous stirring.
      • Step 9: Mineral Oil was added to material from Step 8 under continuous stirring to form a dispersion.
      • Step 10: Granulation aid components were added to the materials from Step 1 and mixed thoroughly followed by kneading for two (2) minutes to form wet mass.
      • Step 11: Wet mass from Step 10 and 75% extra-granular materials from Step 2 were passed simultaneously through cone-mill using six millimeter (6 mm) screen at slow speed and knife forward to form granules.
      • Step 12: Granules from Step 11 and remaining 25% extra-granular materials from Step 2 were passed through #8 mesh granules.
      • Step 13: Granules from Step 12 were mixed together with materials from Step 3 for about five (5) minutes.
      • Step 14: Final granules were compressed using rotary tablet press using 18.0 mm×18.0 mm rounded square shape punch.
    Table 66: Tablet Characterization—Examples 26-28
  • TABLE 66
    Example Example Example
    Parameters 26 27 28
    Weight (mg) 3000 3000 3000
    Shape Rounded Rounded Rounded
    Square Square Square
    Color Light Light Light
    brown to brown to brown to
    brown brown brown
    Width × Length 18.0 × 18.0 18.0 × 18.0 18.0 × 18.0
    Top (mm)
    Width × Length 18.0 × 18.0 18.0 × 18.0 18.0 × 18.0
    Bottom (mm)
    Thickness (mm) 9.1 9.4 8.8
    Disintegration 6 min 7 min 8 min
    Time (min.)
    Hardness (N) 30 25 0
    Friability (%) 0 0 0
  • The results of a texture analysis of the tablets formed according to Example 28 are tabulated in Table 67. The texture analysis was performed using a CT3 Texture Analyzer (Brookfield Engineering) using a TA18 Probe and twenty-five-thousand gram (25,000 g) load cell and five gram (5 g) trigger load, over four millimeters (4 mm) using two millimeter per second (2 mm/s) test speed and using a data rate of twenty (20) points/second.
  • TABLE 67
    Example
    Parameters 28
    Hardness Cycle 1 888
    (g)
    Hardness Cycle 2 132
    (g)
    Deformation at 1.58
    hardness (mm)
    Stringiness Length 0.1
    (mm)
    Adhesiveness (mJ) 0.1
    Cohesiveness 0.04
    Gumminess (g) 33
    Chewiness (mJ) 1.5
    Springiness 4.59
  • The results of a comparative dissolution study involving the tablets formed according to Examples 26-28 are tabulated in Tables 68-70, respectively. The dissolution profiles of Examples 26-28 were compared to a marketed products having similar active strengths. A paddle apparatus rotating at 50 rpm. Nine-hundred milliliters (900 ml) of 0.1 N HCl solution was used as the dissolution medium.
  • TABLE 68
    Time Marketed Example
    point Product 26
    0 0 0
    5 26 15
    10 48 29
    15 67 36
    30 92 55
    45 97 65
    60 98 67
    90 97 71
  • TABLE 69
    Time Marketed Example
    point Product 27
    0 0 0
    5 26 25
    10 48 44
    15 67 59
    30 92 80
    45 97 91
    60 98 94
    90 97 96
  • TABLE 70
    Time Marketed Example
    point Product 28
    0 0 0
    5 26 31
    10 48 51
    15 67 64
    30 92 83
    45 97 92
    60 98 96
    90 97 97
  • Ingredients corresponding to Example 29 are tabulated in Table 71, with the amount of each ingredient given in respective percent by weight (% w/w). The active ingredient in Example 29 is ibuprofen. Ibuprofen particles are coated with hydrophilic hydrogel coating creating effective taste barrier. In Example 29, the active strength of ibuprofen is about 200 mg per unit. Because ibuprofen in Example 29 is coated with hydrophilic hydrogel coating, it has an average assay of about ninety-two (92) percent by weight (% w/w). That is, about 217.4 mg per unit of ibuprofen coated with hydrophilic hydrogel coating is incorporated to composition of Example 29.
  • TABLE 71
    Example
    Ingredients 29
    Granulation Aid Ingredients
    Soybean Oil 9.42
    Zea Mays Oil & BHA & BHT 0.10
    Sorbitol 14.42
    Polyethylene glycol (PEG 400) 5.77
    Povidone K30 1.92
    Liquid Strawberry Flavor 0.58
    Intra-granular Ingredients
    Carnauba Wax 4.81
    Hydrophilic hydrogel coated Ibuprofen 8.36
    Silicified Microcrystalline Cellulose 15.38
    Lactose Monohydrate 3.85
    Sucralose 0.19
    Pregelatinized Corn Starch 6.75
    Crosscarmellose Sodium 2.88
    Xylitol 4.81
    Extra-granular Ingredients
    Pregelatinized Corn Starch 6.06
    Sucralose 0.19
    Silicified Microcrystalline Cellulose 4.81
    Xylitol 2.88
    Lactose Monohydrate 4.81
    Flow Aid Ingredients
    Magnesium Stearate 1.00
    Colloidal Silicon Dioxide 1.00
    Total 100
    • Procedure—Examples 29
      • Step 1: Intra-granular materials (hydrogel coated ibuprofen, carnauba wax, silicified mcc, pregelatinized starch, lactose monohydrate, sucralose, crosscarmellose sodium and xylitol) were passed simultaneously through #30 mesh screen and mixed together.
      • Step 2: Extra-granular materials (pregelatinized starch, silicified mcc, xylitol and lactose monohydrate) were passed simultaneously through #30 mesh screen, mixed together and divided into approximately two parts (75% and 25%).
      • Step 3: magnesium stearate and colloidal silicon dioxide were mixed together and passed together through #30 mesh screen.
      • Step 4: Povidone was added into glycerin and polyethylene glycol under continuous stirring to get clear dispersion.
      • Step 5: Liquid Strawberry Flavor was added to dispersion from Step 4 under continuous stirring to get lump free dispersion.
      • Step 6: Zea mays oil and BHA and BHT was added to soybean oil under continuous stirring to get clear dispersion.
      • Step 7: All granulation aid components except mixture of soybean oil and zea mays oil and BHA and BHT and were added to contents from Step 1 and mixed thoroughly, followed by addition of mixture of soybean oil and zea mays oil and BHA and BHT and mixing to form and granulated wet mass.
      • Step 8: Wet mass from Step 7 was further passed through multi-mill using 6 mm screen.
      • Step 9: Approximately 75% quantity of extra-granular materials from Step 2 and milled granules from Step 8 were passed simultaneously through #8 mesh.
      • Step 10: Remaining quantity (25%) of extra-granular materials and granules from Step 9 were mixed together for 2 minute.
      • Step 11: Materials from Step 3 were added to granules from Step 10 and mixed together for 2 minute.
      • Step 12: Final granules were compressed on rotary tablet press using tooling using an 18.0 mm×18.0 mm rounded square shape punch was used to compress a tablet having a 2600 mg fill weight.
    Table 72: Tablet Characterization—Example 29
  • TABLE 72
    Example
    Parameters 29
    Active Strength 200 mg
    Weight (mg) 2600
    Shape Rounded
    Square
    Color white to off
    white
    Width × Length 18.0 × 18.0
    Top (mm)
    Width × Length 18.0 × 18.0
    Bottom (mm)
    Thickness (mm) 7.0
    Disintegration 07
    Time (min.)
    Hardness (N) 0
    Friability (%) 0.2
  • Ingredients corresponding to Example 30 are tabulated in Table 73, with the amount of each ingredient given in respective percent by weight (% w/w). The active ingredient in Example 30 is acetaminophen. Acetaminophen particles are coated with hydrophilic hydrogel coating creating effective taste barrier. In Example 30 formulation, the active strength of acetaminophen is about 160 mg per unit. Because acetaminophen in Example 30 is coated with hydrophilic hydrogel coating, it has an average assay of about ninety-two (92) percent by weight (% w/w). That is, about 174 mg per unit of ibuprofen coated with hydrophilic hydrogel coating is incorporated to composition of Example 30.
  • TABLE 73
    Example
    Ingredients
    30
    Granulation Aid Ingredients
    Mineral Oil 9.60
    Sorbitol 15.00
    Polyethylene glycol (PEG 400) 6.00
    Povidone K30 2.00
    Liquid Strawberry Flavor 0.60
    Intra-granular Ingredients
    Carnauba Wax 5.00
    Hydrophilic Hydrogel Coated Acetaminophen 6.96
    Silicified Microcrystalline Cellulose 16.00
    Lactose Monohydrate 4.00
    Sucralose 0.20
    Pregelatinized Corn Starch 5.04
    Crosscarmellose Sodium 3.04
    Xylitol 5.00
    Extra-granular Ingredients
    Pregelatinized Corn Starch 6.32
    Sucralose 0.20
    Silicified Microcrystalline Cellulose 5.04
    Xylitol 3.00
    Lactose Monohydrate 5.00
    Flow Aid Ingredients
    Magnesium Stearate 1.00
    Colloidal Silicon Dioxide 1.00
    Total 100
    • Procedure—Examples 30
      • Step 1: Intra-granular materials (hydrogel coated ibuprofen, carnauba wax, silicified mcc, pregelatinized starch, lactose monohydrate, sucralose, crosscarmellose sodium and xylitol) were passed simultaneously through #30 mesh screen and mixed together.
      • Step 2: Extra-granular materials (pregelatinized starch, silicified mcc, xylitol and lactose monohydrate) were passed simultaneously through #30 mesh screen, mixed together and divided into approximately two parts (75% and 25%).
      • Step 3: Magnesium stearate and colloidal silicon dioxide were mixed together and passed together through #30 mesh screen.
      • Step 4: Povidone was added into glycerin and polyethylene glycol under continuous stirring to get clear dispersion.
      • Step 5: Liquid strawberry flavor was added to dispersion from Step 4 under continuous stirring to get lump free dispersion.
      • Step 6: All granulation aid components except mineral oil were added to contents from Step 1 and mixed thoroughly, followed by addition of mineral oil and mixing to form and granulated wet mass.
      • Step 7: Wet mass from Step 6 was further passed through multi-mill using 6 mm screen.
      • Step 8: Approximately 75% quantity of extra-granular materials from Step 2 and milled granules from Step 7 were passed simultaneously through #8 mesh.
      • Step 9: Remaining quantity (25%) of extra-granular materials and granules from Step 8 were mixed together for 2 minutes.
      • Step 10: Materials from Step 3 were added to granules from Step 9 and mixed together for 2 minutes.
      • Step 11: Final granules were compressed on rotary tablet press using tooling using an 18.0 mm×18.0 mm rounded square shape punch was used to compress a tablet having a 2500 mg fill weight.
    Table 74: Tablet Characterization—Example 30
  • TABLE 74
    Example
    Parameters
    30
    Active Strength 200 mg
    Weight (mg) 2500
    Shape Rounded
    Square
    Color white to off
    white
    Width × Length 18.0 × 18.0
    Top (mm)
    Width × Length 18.0 × 18.0
    Bottom (mm)
    Thickness 6.7
    (mm)
    Disintegration 08
    Time (min.)
    Hardness (N) 0
    Friability (%) 0.2
  • The preferred forms of the invention described above are to be used as illustration only and should not be utilized in a limiting sense in interpreting the scope of the present invention. Obvious modifications to the exemplary embodiments, as hereinabove set forth, could be readily made by those skilled in the art without departing from the spirit of the present invention.
  • The inventors hereby state their intent to rely on the Doctrine of Equivalents to determine and access the reasonably fair scope of the present invention as pertains to any apparatus not materially departing from but outside the literal scope of the invention set forth in the following claims.

Claims (25)

What is claimed is:
1. An edible, semi-plastic tablet formed using a tablet press, said tablet comprising:
at least one active ingredient;
said tablet having a hardness of less than about two kiloponds (2 kp) when measured on a tablet hardness tester;
said tablet having a friability of less than about one percent (1%) at about one-hundred (100) rotations.
2. The tablet as claimed in claim 1,
said tablet having a hardness of less than about one kilopond (1 kp) when measured on a tablet hardness tester.
3. The tablet as claimed in claim 3,
said tablet having a hardness of about zero kilopond (0 kp) when measured on a tablet hardness tester.
4. The tablet as claimed in claim 1,
said tablet having a friability of less than about one percent (1%) at about two-hundred (200) rotations.
5. The tablet as claimed in claim 4,
said tablet having a friability of less than about one percent (1%) at about three-hundred (300) rotations.
6. The tablet as claimed in claim 1,
said active ingredient being a pharmaceutical ingredient;
said pharmaceutical ingredient being selected from the group consisting of analgesic agents, anesthetic agents, anthelmintic agents, antibiotics, anti-depressants, antiemetic agents, antifungal agents, antihistamines, antiprotozoal agents, antithyroid agents, appetite stimulants, agents used to treat attention-deficit hyperactivity disorder, cardiovascular agents, corticosteroids, parasiticidal agents, steroids, and combinations thereof.
7. The tablet as claimed in claim 6,
said active ingredient being selected from the group consisting of acetaminophen, carprofen, cefpodoxime proxetil, deracoxib, enrofloxacin, ibuprofen,
marbofloxacin, pimobendan, and combinations thereof.
8. The tablet as claimed in claim 1, said tablet further comprising:
at least one granulation aid ingredient,
at least one intra-granular ingredient, and
at least one extra-granular ingredient.
9. The tablet as claimed in claim 8,
said granulation aid ingredient being selected from the group consisting of antioxidants, binding agents, coloring agents, humectants, palatability enhancers, plasticizers, preservatives, texturing agents, and combinations thereof.
10. The tablet as claimed in claim 9,
said granulation aid ingredient being selected from the group consisting of brown iron oxide, butylated hydroxyanisole, butylated hydroxytoluene, citric acid, cremophor, glycerin, liquid strawberry flavor, mineral oil, polyethylene glycol, polysorbate, povidone, sorbitol, soybean oil, tartaric acid, zea mays oil, and combinations thereof.
12. The tablet as claimed in claim 8,
said intra-granular ingredient being selected from the group consisting of binding agents, diluents, disintegrants, flavor agents, oil absorbing agents, palatability enhancers, plasticizers, surfactants, texturing agents, and combinations thereof.
13. The tablet as claimed in claim 12,
said intra-granular ingredient being selected from the group consisting of beef flavor, calcium carboxymethylcellulose, calcium sulfate dihydrate, carnauba wax, croscarmellose sodium, lactose, lactose monohydrate, mannitol, microcrystalline cellulose, polycarbophil, polyethylene glycol, pregelatinized corn starch, silicified microcrystalline cellulose, sodium carboxymethylcellulose, sodium lauryl sulfate, soluplus, sucralose, xylitol, and combinations thereof.
14. The tablet as claimed in claim 8,
said extra-granular ingredient being selected from the group consisting of binding agents, diluents, disintegrants, flavor agents, oil absorbing agents, palatability enhancers, plasticizers, surfactants, texturing agents, and combinations thereof.
15. The tablet as claimed in claim 14,
said extra-granular ingredient being selected from the group consisting of beef flavor, calcium carboxymethylcellulose, calcium sulfate dihydrate, croscarmellose sodium, lactose, lactose monohydrate, maltodextrin, poly(ethylene) oxide, polyethylene glycol, pregelatinized corn starch, silicified microcrystalline cellulose, sodium carboxymethylcellulose, sodium lauryl sulfate, sucralose, xylitol, and combinations thereof.
16. The tablet as claimed in claim 8,
said granulation aid ingredient being present at a concentration of more than about ten percent (10%) by weight based on the total weight of the tablet.
17. The tablet as claimed in claim 16,
said granulation aid ingredient being present at a concentration from more than about ten percent (10%) to about fifty percent (50%) by weight based on the total weight of the tablet.
18. The tablet as claimed in claim 8,
said intra-granular ingredient being present at a concentration of more than about fifteen percent (15%) by weight based on the total weight of the tablet.
19. The tablet as claimed in claim 18,
said intra-granular ingredient being present at a concentration from more than about fifteen percent (15%) to about seventy-five percent (75%) by weight based on the total weight of the tablet.
20. The tablet as claimed in claim 8,
said extra-granular ingredient being present at a concentration of more than about five percent (5%) by weight based on the total weight of the tablet.
21. The tablet as claimed in claim 20,
said extra-granular ingredient being present at a concentration from more than about five percent (5%) to about fifty percent (50%) by weight based on the total weight of the tablet.
22. The tablet as claimed in claim 1, said tablet further comprising:
at least one flow aid ingredient;
said at least one flow aid ingredient being selected from the group consisting of colloidal silicon dioxide, magnesium stearate, stearic acid, sodium lauryl sulfate, sodium stearyl fumarate, talc, and combinations thereof.
23. The tablet as claimed in claim 1,
said active ingredient being present at a concentration of more than about one one-hundredth percent (0.01%) by weight based on the total weight of the tablet.
24. The tablet as claimed in claim 23,
said active ingredient being present at a concentration from more than about one one-hundredth percent (0.01%) to about fifty percent (50%) by weight based on the total weight of the tablet.
25. An edible, semi-plastic tablet formed using a tablet press, said tablet comprising:
at least one active ingredient;
said tablet having a weight of more than about three-hundred milligrams (300 mg);
said tablet having a hardness of less than about one kilopond (1 kp) when measured on a tablet hardness tester;
said tablet having a friability of less than about one percent (1%) at about one-hundred (100) rotations.
26. A process for manufacture of an edible, semi-plastic tablet unit dosage form for the oral administration of an active ingredient comprising the steps of:
(a) combining said active ingredient with at least one ingredient to form a soft-chew mass; and
(b) compressing said soft-chew mass using a tablet press to form a tablet, wherein said tablet has a hardness of less than about two kiloponds (2 kp) when measured on a tablet hardness tester, and a friability of less than about one percent (1%) at about one-hundred (100) rotations.
US16/140,477 2015-12-19 2018-09-24 Soft-chew tablet pharmaceutical formulations Abandoned US20190022013A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US16/140,477 US20190022013A1 (en) 2015-12-19 2018-09-24 Soft-chew tablet pharmaceutical formulations
US16/894,514 US11633361B2 (en) 2015-12-19 2020-06-05 Soft chew pharmaceutical formulations
US17/893,265 US20220409547A1 (en) 2015-12-19 2022-08-23 Soft-Chew Tablet Pharmaceutical Formulations

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562269951P 2015-12-19 2015-12-19
PCT/US2016/067443 WO2017106812A1 (en) 2015-12-19 2016-12-19 Soft-chew tablet pharmaceutical formulations
US15/629,354 US10117831B2 (en) 2015-12-19 2017-06-21 Soft chew pharmaceutical formulations
US16/140,477 US20190022013A1 (en) 2015-12-19 2018-09-24 Soft-chew tablet pharmaceutical formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/629,354 Continuation-In-Part US10117831B2 (en) 2015-12-19 2017-06-21 Soft chew pharmaceutical formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/894,514 Continuation US11633361B2 (en) 2015-12-19 2020-06-05 Soft chew pharmaceutical formulations

Publications (1)

Publication Number Publication Date
US20190022013A1 true US20190022013A1 (en) 2019-01-24

Family

ID=65014293

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/140,477 Abandoned US20190022013A1 (en) 2015-12-19 2018-09-24 Soft-chew tablet pharmaceutical formulations
US16/894,514 Active US11633361B2 (en) 2015-12-19 2020-06-05 Soft chew pharmaceutical formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/894,514 Active US11633361B2 (en) 2015-12-19 2020-06-05 Soft chew pharmaceutical formulations

Country Status (1)

Country Link
US (2) US20190022013A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210177842A1 (en) * 2019-10-23 2021-06-17 Piedmont Animal Health Inc. Pimobendan formulation and method of use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205379A1 (en) * 2022-04-21 2023-10-26 First Time Us Generics Llc Tablet press compression tooling assembly for the formation of soft-chew tablets and related methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6814978B2 (en) * 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US20100010101A1 (en) * 2000-07-05 2010-01-14 Capricorn Pharma, Inc. Rapid-Melt Compositions and Methods of Making Same
US20140141055A1 (en) * 2012-11-20 2014-05-22 Dominique Kluger Manufacturing of semi-plastic pharmaceutical dosage units

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327076A (en) 1980-11-17 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4327077A (en) 1981-05-29 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4582709A (en) 1985-02-08 1986-04-15 Warner-Lambert Company Chewable mineral supplement
CA1297035C (en) 1987-12-29 1992-03-10 Warner-Lambert Canada Inc. Chewable, non-gritty calcium citrate tablet
US5380535A (en) 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
JP2640570B2 (en) 1992-01-13 1997-08-13 ファイザー インク． Manufacturing tablets with increased strength
GR1002332B (en) 1992-05-21 1996-05-16 Mcneil-Ppc Inc. Novel simethicone containing pharmaceutical compositions.
CA2110313C (en) 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5637313A (en) 1994-12-16 1997-06-10 Watson Laboratories, Inc. Chewable dosage forms
AUPN940796A0 (en) 1996-04-23 1996-05-16 F.H. Faulding & Co. Limited Taste masked pharmaceutical compositions
US6517886B1 (en) 1997-06-24 2003-02-11 Biovail Corporation International Positive hydration method of preparing confectionery and the resulting product
US5840334A (en) 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
US6432442B1 (en) 1998-02-23 2002-08-13 Mcneil-Ppc, Inc. Chewable product
US6270790B1 (en) 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
US20060121092A1 (en) 1999-04-06 2006-06-08 Ream Ronald L Methods of producing coated products including active agent and products regarding same
US20060121093A1 (en) 1999-04-06 2006-06-08 Ream Ronald L Tableted products including active agent
US6495177B1 (en) 1999-08-13 2002-12-17 Warner Chilcott Laboratories Ireland Limited Orally dissolvable nutritional supplement
JP4040878B2 (en) * 1999-12-09 2008-01-30 レキット ベンキーザー ヘルスケア （ユーケイ） リミテッド Remedy
US7914811B2 (en) 2001-06-29 2011-03-29 Mcneil-Ppc, Inc. Brittle-coating, soft core dosage form
BR0206086A (en) 2001-09-28 2003-12-23 Mcneil Ppc Inc Modified Release Dosage Forms
US6753009B2 (en) 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
US20060039967A1 (en) 2002-08-12 2006-02-23 Motohiro Ohta Amino acid-containing chewable
KR101030735B1 (en) 2002-08-13 2011-04-26 인터벳 인터내셔널 비.브이. Compositions and process for delivering an additive
US20040109889A1 (en) 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US20040265373A1 (en) 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
US20040265372A1 (en) 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
WO2005041935A1 (en) 2003-10-21 2005-05-12 Alpharma, Inc. Pharmaceutical formulations containing quetiapine
US9271904B2 (en) 2003-11-21 2016-03-01 Intercontinental Great Brands Llc Controlled release oral delivery systems
US7318920B2 (en) 2004-09-27 2008-01-15 Ez-Med Company Low water activity nutritional product having beneficial microbial and high oil content
US8758814B2 (en) 2004-10-08 2014-06-24 Mcneil-Ppc, Inc. Chewable enteric coated aspirin tablets
EP1895992A4 (en) 2005-05-23 2012-03-28 Kraft Foods Global Brands Llc Compressible gum based delivery systems for the release of ingredients
US20070098746A1 (en) 2005-11-02 2007-05-03 Nichols William M Multi-layered coating technology for taste masking
EP1945181B1 (en) 2005-11-09 2023-03-29 Wm. Wrigley Jr. Company Coated pharmaceutical composition for buccal release which comprises a consumable center and a medicament-containing coating
CA2629957C (en) 2005-11-15 2012-07-24 Wm. Wrigley Jr. Company Tablets comprising a core and a medicament-containing coating for buccal release
CA2629954A1 (en) 2005-11-15 2007-05-24 Wm. Wrigley Jr. Company Methods of producing coated products including active agent and products regarding same
US20070128251A1 (en) 2005-12-07 2007-06-07 Piedmont Pharmaceuticals, Inc. Process for manufacturing chewable dosage forms for drug delivery and products thereof
US7955632B2 (en) 2005-12-07 2011-06-07 Bayer B.V. Process for manufacturing chewable dosage forms for drug delivery and products thereof
US20080008742A1 (en) 2006-06-29 2008-01-10 Capricorn Pharma, Inc. Chewy products and methods for making the same
US9820977B2 (en) 2008-10-03 2017-11-21 Bayer Healthcare Llc Systemic treatment of blood-sucking and blood-consuming parasites by oral administration of a parasiticidal agent
GB0907019D0 (en) 2009-04-24 2009-06-03 Oxford Nutrascience Ltd Pharmaceutical,therapeutic or nutritional delivery systems for functional ingredients
US8807979B2 (en) 2009-09-24 2014-08-19 Mcneil-Ppc, Inc. Machine for the manufacture of dosage forms utilizing radiofrequency energy
WO2011079074A1 (en) 2009-12-24 2011-06-30 Acura Phamaceuticals, Inc. Pharmaceutical compositions for deterring misuse, abuse, and diversion
WO2012021819A1 (en) 2010-08-13 2012-02-16 Acura Pharmaceuticals, Inc. Optimized niacin compositions in pharmaceutical products
WO2012072824A1 (en) 2010-12-03 2012-06-07 Novartis Ag Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
WO2012090194A2 (en) 2010-12-29 2012-07-05 Abrham Galya Compositions and methods for treating a skin disorder
US9655849B2 (en) 2011-03-18 2017-05-23 Particle Dynamics International, Llc Solid particulate compositions comprising coenzyme Q10
US8623332B2 (en) 2011-07-06 2014-01-07 Fertin Pharma A/S Chewing gum having sustained release of nicotine
US20130071476A1 (en) 2011-08-19 2013-03-21 Subraman Rao Cherukuri Rapid Melt Controlled Release Taste-Masked Compositions
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
EP3137080B1 (en) 2014-04-28 2019-09-04 Orphomed, Inc. Pharmaceutically active dimers linked through phenolic hydroxyl groups

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100010101A1 (en) * 2000-07-05 2010-01-14 Capricorn Pharma, Inc. Rapid-Melt Compositions and Methods of Making Same
US6814978B2 (en) * 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US20140141055A1 (en) * 2012-11-20 2014-05-22 Dominique Kluger Manufacturing of semi-plastic pharmaceutical dosage units

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210177842A1 (en) * 2019-10-23 2021-06-17 Piedmont Animal Health Inc. Pimobendan formulation and method of use thereof

Also Published As

Publication number Publication date
US20200297643A1 (en) 2020-09-24
US11633361B2 (en) 2023-04-25

Similar Documents

Publication Publication Date Title
US10117831B2 (en) Soft chew pharmaceutical formulations
US7815937B2 (en) Quick dissolve compositions and tablets based thereon
CN100379407C (en) Process for manufacturing bite-dispersion tablets
KR100725833B1 (en) Polymer based rapidly dissolving tablets and production processes thereof
US6358526B1 (en) Method of making tablets and tablet compositions produced therefrom
US20110142931A1 (en) Soft tablet containing dextrose monohydrate
US20100010101A1 (en) Rapid-Melt Compositions and Methods of Making Same
US20090098211A1 (en) Solid dosage forms
JPH10510817A (en) Chewable preparation
JP2000264836A (en) Intraoral disintegration-type tablet and its production
HU226456B1 (en) Sustained-release hydrogel preparation
US8367106B2 (en) Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US20130039981A1 (en) Quick Dissolving, Long Acting Zinc Therapeutic Formulations
US20040014680A1 (en) Medicinal compositions quickly disintegrating in the oral cavity and process for producing the same
US20120082729A1 (en) Quick dissolve compositions and tablets based thereon
WO2007086457A1 (en) Quickly disintegrating tablet produced by direct dry-tabletting
US11633361B2 (en) Soft chew pharmaceutical formulations
JP6998210B2 (en) Particle composition for easy-to-take solid preparation and easy-to-take solid preparation containing the particle composition
JP3418274B2 (en) Tablets with good oral feel
US20220409547A1 (en) Soft-Chew Tablet Pharmaceutical Formulations
JP3884056B1 (en) Method for producing intraoral rapidly disintegrating tablet
JP6513702B2 (en) Super fast disintegrating tablet and method for producing the same
KR20110007065A (en) Orally disintegrating tablet and manufacturing method of the same
WO2023205379A1 (en) Tablet press compression tooling assembly for the formation of soft-chew tablets and related methods
US20130072578A1 (en) Orodispersible tablets of erythritol and isomalt

Legal Events

Date Code Title Description
AS Assignment

Owner name: FIRST TIME US GENERICS LLC, PENNSYLVANIA

Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNORS:DIXIT, MANESH A;PAWAR, VAIBHAV;PATEL, RUSHI;AND OTHERS;SIGNING DATES FROM 20161220 TO 20170105;REEL/FRAME:046955/0687

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: USPHARMA LTD., FLORIDA

Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:FIRST TIME US GENERICS LLC;REEL/FRAME:064937/0656

Effective date: 20230510